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1. Summary 
Castration resistant prostate cancer (CRPC) is the most aggressive form of prostate 
cancer (PCa).  For the development of novel therapeutic targets for CRPC, it is key to 
decipher the molecular alterations underlying this lethal disease. Next generation 
sequencing (NGS) technologies have revolutionized cancer research by detecting 
genomic alterations, nucleotide substitutions, insertions, deletions and copy number 
alterations. This project was focused on identifying novel genes involved in CRPC by 
assessing somatic copy number alterations (SCNA) using whole exome sequencing on 
five CRPC and paired normal formalin fixed paraffin embedded (FFPE) samples by 
the SOLiD4 next generation sequencing platform.   
The central aim of this study was the identification of therapeutic targets for CRPC. 
Due to the unavailability and scarcity of fresh frozen CRPC material for research 
purposes, the primary aim of this study was to compare the DNA, RNA and protein 
integrity in fixed tissues obtained from pathology archives. Secondly, validity of 
formalin fixed paraffin embedded (FFPE) and fresh frozen PCa tissue, from the same 
patient, was determined by whole exome sequencing.  A large data overlap between 
both fixed tissue types was observed. This eventually led to the main objective of the 
study involving the identification of therapeutic targets for CRPC.   
FFPE and HOPE fixed specimen were comparable in DNA quality for downstream 
research purposes. Furthermore, FFPE tumor and fresh frozen tumor exome 
sequencing data, from the same patient, showed an overlap in the SNV analysis. This  
led to the central aim which included the analysis of somatic copy number alterations 
(SCNA) using whole exome sequencing on five CRPC and paired normal FFPE 
samples by the SOLiD4 next generation sequencing platform. The sequencing data 
identified two genes, YWHAZ and PTK2. Both genes, located on chromosome 8, were 
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amplified on all five sequenced patients. Furthermore, the amplification frequency of 
both genes increased depending on the stage of PCa: prostate confined or localized 
PCa, lymph node metastasized PCa and CRPC. YWHAZ knockdown in the PC-3 cell 
line impaired proliferation and migration. Similarly, PTK2 inhibition, using a 
pharmacological inhibitor, TAE226 inhibitor, significantly affected both cell 
migration and proliferation at a concentration of 10 µM. Overall, these findings 
suggest that inhibiting both YWHAZ and PTK2 could potentially delay cancer 
progression in patients harboring the amplification of the latter genes. Furthermore, 
FFPE tissue could be used as a promising alternative to fresh frozen tissue for NGS 
technologies.  	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2. Introduction 
Prostate cancer (PCa) is the second largest cause of cancer related death in men of the 
western world, accounting for more than 250,000 deaths a year (Figure 1) (1). It has 
been reported that 1 out of every 6 men will be diagnosed with PCa and 1 out of every 
3 diagnosed men will die of this disease (2). Various genetic alterations such as 
amplifications, deletions, mutations, substitutions, and rearrangements, have been 
studied to trigger the onset of disease. Unfortunately, due to its poorly understood 
molecular mechanisms, in addition to its highly heterogeneous and complex nature, 
treatment options for this disease remain a challenge (3).   
 
 
Figure 1:  Prostate cancer diagnosis world wide. 
The most commonly diagnosed cancer among men worldwide in 2008. Prostate cancer (purple) is the 
second largest cause of death in men of the western world. (adapted from Ferlay et al. 2010). (4)  
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2.1 The Prostate  
The prostate is a walnut sized exocrine gland of the male reproductive organ. It 
surrounds the urethra and located at the base of the urinary bladder. The function of 
the prostate is the secretion of semen, with spermatozoa and seminal vesicle fluid. 
The secretions from the seminal make semen alkaline in nature, which aids in 
prolonging the lifespan of sperm (5). The prostate is architecturally defined as having 
four zones: the central, periurethral transition, peripheral, and fibromuscular stroma 
(6). These prostate zones consist of parenchymal cells, namely luminal epithelial 
cells, basal epithelial cells and fibromuscular stromal cells. The luminal epithelial 
cells express high levels of androgen receptor (AR). The basal epithelial cells express 
AR at low undetectable levels. A rare subset of cells known as the neuroendocrine 
cells expressing endocrine markers are also present (7).  
In brief, the prostate is regulated by androgens, namely testosterone and 5-alpha-di 
hyrdotestosterone, produced by the male testicles. These hormones belong to the 
group of steroid hormones. The conversion of cholesterol to testosterone involves 
various steps (Figure 2) and studies have shown that 5% of testosterone is converted 
to dihydrotestosterone (DHT) through the 5-alpha-reductase catalyzed conversion in 
the cells of the external male genitalia, the prostate and the bulbourethral glands. DHT 
also exhibits a higher affinity to AR then testosterone. Furthermore, this highly active 
metabolite binds to several DNA sequences to initiate transcription. This results in the 
development and differentiation of the prostate (8).  
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Figure 2:  Conversion of cholesterol to testosterone.  
DHT plays an active role in prostate cancer development and progression (adapted from Chen et al, 
2006) . (9) 
 
2.2 Cancer Stages and Types    
PCa can be broadly categorized into three stages: localized PCa, lymph node 
metastasized PCa and distant metastasized PCa (Figure 3). Localized PCa is cancer 
that is confined to the prostate gland and is curable in majority of the cases. Lymph 
node metastasized PCa includes the spreading of the cancer through the lymph system 
consisting of lymph nodes and lymph vessels. The most lethal form of this disease is 
distant metastasized PCa, also known as castration resistant prostate cancer (CRPC), 
where the cancer has spread to distant tissues through the blood stream (10). The bone 
is the most frequent site of metastasis for PCa.  
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Figure 3:  Prostate cancer types. 
(A) Human schematic representing localized PCa, lymph node metastasized PCa and distant metastasis 
to the brain. (B) Metastasis of tumor cells from the site of origin to different locations in the body via 
the bloodstream (adapted from Braun et al. 2010) (11) 
 
Additionally, PCa is commonly seen to occur in two types, namely adenocarcinoma 
and small cell carcinoma. Adenocarcinoma is the most common form of PCa, which 
arises from the cells of the glands. As most of the cells in the prostate are glandular 
cells, adenocarcinoma has a tendency to develop metastatic potential. The rare but 
highly aggressive form of PCa is small cell carcinoma. Small cell carcinomas are 
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aggressive because they are AR negative and patients do not benefit from hormone 
treatments (12).  
 
2.3 Genomic Events Leading to PCa Initiation and Progression 
In-depth analysis using comparative genomic hybridization (CGH) studies has 
identified various somatic alterations in PCa. These alterations include chromosomal 
losses at 3p, 8p,10q, 13q, and 17p. The 8q region is seen to be extensively amplified 
in PCa patients (13). Many genes lie in the regions of gains and losses known to be 
key players in PCa initiation and progression such as NKX3.1 deletion, MYC 
amplification, PTEN (phosphatase and tensin homolog) deletion, EZH2 up-regulation, 
and TMRPSS2-ERG gene fusions. 
a) NKX3.1 deletion: The NKX3.1 homeobox gene located on 8p is frequently seen to 
be down regulated in advanced PCa. Through the progression of PCa, several studies 
indicate the complete loss of the gene or a reduction in protein expression. In mice, 
NKX3.1 regulates prostate epithelial differentiation and stem cell function. In humans, 
the gene protects against DNA damage and regulates inflammation (14). Therefore, 
the absence or decrease of NKX3.1 expression in PCa progression suggests a role as a 
potential tumor suppressor in PCa.  
b) MYC amplification: MYC is an oncogene situated in the 8q24 chromosomal region 
and is frequently amplified and over-expressed in advanced PCa. This gene is a 
transcription factor regulating metabolism, development, apoptosis, cell proliferation 
and differentiation (15). MYC amplifications often occur in combination with other 
genetic alterations leading to a cumulative negative effect (16). Studies have also 
shown that forced expression of MYC produces immortalized nontumorigenic human 
prostate epithelial cells (17). 
7
	  	  	  
c) PTEN (phosphatase and tensin homolog) deletion: PTEN is a potential tumor 
suppressor gene situated on 10q23. This gene is reported to be frequently deleted in 
various cancers. Previous publications have reported that the loss of PTEN activates 
the AKT and JNK signaling pathways therefore leading to the development of CRPC 
(18, 19). In PCa, conflicting data regarding the single allelic deletion of PTEN, 
mutation of the second allele, and the reduced expression of PTEN have been 
published (20). Interestingly, through the progression of PCa, PTEN copy number loss 
correlates to the aggressive nature of the disease. PTEN, MYC and NKX3.1 genetic 
alterations often occur together exhibiting a cumulative negative effect on patient 
health. With reference to cancer cell lines, human cell lines exhibiting decreased 
PTEN expression and PTEN deleted mouse cell PCa lines develop a castration 
resistant phenotype (21). The molecular mechanisms behind PTEN alterations in PCa 
remain to be investigated.  
d) EZH2 up-regulation: The up-regulation of EZH2 through amplification is a 
common event in advanced PCa (22). The gene is part of the Polycomb family and 
codes for histone lysine methyltransferase. EZH2 targets, which also include NKX3.1, 
play an active role in metastasis by the activation of the Ras and NF-ΚB pathways 
(23). The polycomb family of genes function as inhibitors of gene expression by 
forming multimeric complexes of proteins. These structures alter chromatin structure. 
This family of genes regulates expression of cell cycle genes and HOX genes. These 
latter genes regulate proliferation (24). 
e) TMRPSS2-ERG gene fusions: The most commonly occurring gene fusions in PCa 
involve the ETS transcription factors. The ETS transcription factors regulate DNA 
binding, both positively and negatively, to transcriptional regulatory properties on the 
same domain. Many ETS domain proteins are linked to cancer via various 
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mechanisms, which include their function in chromosomal translocations or 
overexpression/down-regulation in cancers. Similarly, the family of transcription 
factors also regulate proto-oncogenes or tumor suppressor proteins by their ability to 
transduce signals from oncogenically activated signaling cascades (25). The 
TMPRSS2-ERG gene fusion is the most common gene fusion occurring in 15-80% of 
PCa patients. The large variation is due to the ethnicity, age, family history etc. The 
TMPRSS2 gene codes for a serine protease that is expressed in the epithelium of the 
prostate (26). The fusion occurs between the 5’exon of TMPRSS2 and the coding 
sequence of ERG. The exact location of the fusion is on 21q22.2-22.3 resulting in two 
products, an insertion through deletion or a translocation (Figure 4). 
 
 
Figure 4:  ERG rearrangement.  
Dual colored fluorescent in situ hybridization (FISH) assay to detect ERG break-apart. (A) A wild type 
ERG rearranged nucleus. (B) ERG rearrangement through deletion. (C) ERG rearrangement through 
insertion (adapted from Braun et al., 2011). (27) 
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Studies show that in patients harboring the fusion, the TMPRSS2 promoter contains 
the responsive promoter elements thus leading to androgen dependent ETS gene 
overexpression (28).  This fusion may be a result of radiation and other genotoxic 
stress leading to double stranded breaks within the DNA. TMPRSS2 is also seen to 
fuse with ETV1, ETV4 and ETV5. Another gene fusion seen in very low frequencies is 
SLC45A3 gene fusions with ERG, ETV1 and ETV5(29).  
The most commonly seen TMPRSS2-ERG gene results in the TMPRSS2 exon 1 fusing 
with ERG exon 4, referred to as Type III isoform. This is seen in 80-90% of the gene 
fusions. The second most common isoform results in the fusion between TMPRSS2 
exon 2 and ERG exon 4, referred to as Type IV (Figure 5). The Type IV fusion result 
in enhanced proliferation and invasion of PCa epithelial cells (30).  
 
 
Figure 5: Role of TMPRSS2-ERG gene fusions.  
The most commonly seen isoforms of the gene fusion include the Type III and Type IV.   These 
fusions lead to the up and down-regulations of various pathways involved in PCa progression (adapted 
from Tindall et al, 2011) . (31) 
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Extensive studies on the ERG gene have shown its role in acting as an oncogene and 
promoting tumor formation. It interacts with the c-JUN and AP-1 pathways to 
promote growth, therefore indication the role of the gene fusion in the same (30). The 
VCaP cell line, a PCa cell line derived from a vertebral metastatic lesion, is the only 
cell line harboring the Type III gene rearrangement. Furthermore, studies have shown 
that the Type III isoform induces increased invasion, proliferation and motility and 
decreased differentiation (30).  
e) Altered Pathways in PCa: One significant pathway that is altered in PCa is the up-
regulation of the PI3K/AKT/mTOR signaling cascade. The tumor suppressor gene 
PTEN negatively regulates this pathway and loss of PTEN results in increase of cell 
growth, proliferation, and survival (32). In addition, the ERK/MAPK signaling 
pathway is also frequently activated in advanced PCa. Similarly, the RAS and RAF 
pathways are also up-regulated, possibly via mutations, in PCa (32). Inhibition of the 
above mentioned pathways has decreased tumor cell development and enhanced 
apoptosis. These characteristics have enhanced the role of these pathways as potential 
combinational therapeutic targets for treated PCa (33, 34).  
 
2.4 Processes Promoting Prostate Cancer Progression 
Various factors lead to PCa progression in men. Amongst these factors, age is 
considered to be the most significant risk factor leading to the development of PCa. 
Along with age, several environmental and physiological processes contribute to the 
progression of the disease. Several studies have identified inflammation, oxidative 
stress, telomere shortening and cell senescence also to play a key role in promoting 
PCa (7, 35, 36) .  
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a) Inflammation: Chronic inflammation in the presence of the expression of various 
chemokines has been reported to be linked to PCa progression (37). In older men, 
regions of frequent inflammation have been referred to as “proliferative inflammatory 
atrophy (PIA). These regions exhibit increased epithelial proliferation (38).   
b) Oxidative Stress: An imbalance in the detoxifying enzymes and the reactive 
oxygen species (ROS) leads to lipid, DNA and protein damage, which is a major 
cause of oxidative stress. It is speculated that the prostate gland is highly vulnerable to 
oxidative stress due to the processes such as inflammation, hormonal dysregulation, 
diet, and epigenetic modifications. The epigenetic silencing of the gene, GSTP1, 
belonging to the glutathione S-transferase family is a classic example. The function of 
this gene is to initiate the detoxification of the ROS.  In PCa, the gene is inactivated 
due to promoter hypermethylation thereby subjecting DNA to further genome 
damaging stress that may lead to malignant cancer progression. Another example is 
APE/Ref 1, a multifunctional enzyme controlling other enzymes involved in 
detoxification and base excision repair. This enzyme is up-regulated in PCa, but, PCa 
patients harboring a polymorphism in the APE gene are susceptible to developing 
cancer due to the loss of function of the gene (39).  
c) Telomere shortening: Telomeres are repetitive sequencing situated on the ends of 
chromosomes to denote chromosomal stability. Studies have correlated the effects of 
telomere shortening during prostate carcinogenesis, but the exact mechanism of action 
still remains unclear (40).  
d) Senescence: In PCa, oncogene driven senescence plays a key role in tumor 
suppression. Oncogenes, such as FOXm1, p53, Rb, c-Myc, drive senescence through 
replicative stress or the formation of ROS. Several senescence markers such as SA-β-
Gal, p14arf, p16ink4a are used to identify indolent phenotype from the aggressive (41). 
12
	  	  	  
 
2.5 Androgen Receptor and PCa 
AR plays a key role in prostate cancer. The AR gene is part of the steroid hormone 
receptor superfamily of genes. It is a nuclear transcription factor located on the X 
chromosome. Structurally, it consists of 8 exons and is divided into three distinct 
domains: the N terminal domain (NTD), the deoxyribonucleic acid (DNA) binding 
domain, and the ligand binding domain (LBD). The “hinge domain” links the LBD to 
the DBD (42)  (Figure 6).  
 
Figure 6: Schematic representation of AR on Chromosome X. (43) 
 
Upon the binding of testosterone or DHT to the AR on the target cell, several heat 
shock proteins are dissociated to the cytoplasm.  This is followed by a conformational 
change in the structure of the receptor resulting in its translocation to the nucleus. In 
the nucleus the receptor binds to specific DNA sequences and dimerizes resulting in 
the recruitment of coactivators such as  ARA70, ARA55, ARA54, ARA267-α, Smad-
3,and AIB1 (44).  These steps lead to the activation of transcription of target genes 
such Prostate Specific Antigen (PSA) in the prostate, cyclin-dependent kinase 
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inhibitor 1A, Ezrin, Matrix metalloproteinase and SREBF chaperone. AR also recruits 
co-repressors such as Cyclin D1, RAD9 homologs, Nuclear receptor co-repressor 1 
and others (45-52).  Therefore, AR is essential in maintaining homeostasis in both the 
epithelial and stromal tissues of the normal prostate.  
Apart from the ligand binding activity of AR, several post translational modifications 
also play a major role in AR function. AR phosphorylation initiates the activation of 
growth factors, which are important for prostate epithelial cell growth and function. 
Acetylation of the AR is required for PCa proliferation and survival. This modification 
allows for the recruitment of co-regulators of the target genes and inhibits apoptosis 
mediated by MEKK1 and JNK (53). Sumoylation of AR is necessary for the 
localization, degradation and activation of AR. Furthermore, AR ubiquitination plays 
a major role in enhancing the transcriptional of AR in the LNCaP cells (54). 
More generalized function of the AR include the regulation of the cell cycle. AR up-
regulates genes such as Skp2, Cyclin D1, CDK1, and mTOR; and down-regulates 
genes such as p21, and p27, thereby facilitating cellular replication and G1/S cell 
cycle transition. AR also regulates Cyclin A and CDK2 activity by triggering the S and 
G2 phases of the cell cycle (55). Another important function of AR is the inhibition of 
apoptosis. It up-regulates Fas/FasL associated death domain protein like inhibitory 
protein (FLIP) that in turn inhibits the death induced signaling complex (DISC).  
Furthermore, the Wnt pathway downstream modulator, Beta-catenin, also interacts 
with AR and enhances gene transcription. 
 
2.6 Available Treatment Options for PCa 
PCa can be detected by a digital rectal exam, increased PSA levels in blood, MRI, CT 
scan, and surgery. PSA is a part of the kallikrein family and is an androgen regulated 
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serine protease that is secreted by both malignant and benign prostate epithelial cells. 
PSA values are influenced by several factors such as age, cancer, race and 
inflammation (56). Based on tumor growth and spread, the cancer is characterized 
based on the TNM system. T(umor) – measures the size of the tumor, N(odes)- 
accounts for spreading of the cancer to the lymph nodes and M(etastasis) – describes 
spreading of the cancer to various distant tissues through the blood stream. 
Furthermore, PCa stages I-IV describe the aggressiveness of the disease, with I 
denoting cancer confined to the prostate and IV denoting a highly aggressive and 
lethal form PCa (57). 
Early stage treatment options for the PCa include radiation and surgery (radical 
prostatectomy). When closely monitored, 50% of patients benefit from this treatment. 
On the other hand, the lethal form of the disease, CRPC, has very limited treatment 
options and an average survival rate of a few months to a couple of years (58, 59). 
Thus, much needs to be done in developing treatment options for CRPC patients, as it 
still remains a major challenge.   
The current and most commonly used treatment option for CRPC is androgen ablation 
therapy. The therapy is aimed at blocking the production of androgen that in turn 
regresses the growth and spread of PCa cells. Some FDA approved drugs include 
Abiraterone, a CYP17 inhibitor decreasing testosterone levels, and MDV-3100, an 
AR antagonist (60-62). Initially, patients respond well to treatment, but they are never 
completely cured of the disease, eventually resulting in recurrence and cancer related 
death. The major challenge involving the androgen ablation therapy is the ability of 
the PCa cell to survive and proliferate in the absence of androgen. To escape the 
androgen blockade, approximately one third of CRPC patient tumors develop AR 
amplifications (63). Other studies have shown that androgen ablation therapy results 
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in a gain of function mutation in the AR resulting in increased protein stability, 
sensitivity to minute amounts of androgens, sensitivity to other steroid hormones and 
increased recruitment of other AR coactivator proteins.  Alternative splice forms of 
active AR variants often develop in CRPC (64). Lastly, another escape mechanism is 
the production of endogenously expressed androgen synthetic enzymes resulting in 
the de novo androgen synthesis and conversion of weaker androgens to testosterone 
and dihydrotestosterone.     
 
2.7 Pathology Archiving of PCa Samples 
For research purposes, PCa samples can be obtained in three forms: fresh frozen, 
formalin fixed paraffin embedded (FFPE) and hepes-glutamic acid (buffer mediated 
organic solvent protection effect (HOPE) fixation.  
Fresh frozen samples are known to be the ideal source of material for genomic and 
proteomic analysis, with the least amount of degradation. Unfortunately, they are 
sparsely available and require labor-intensive protocols for storage and handling. 
Thus, storing fresh frozen material is a very tedious and cost intensive process. On the 
other hand, FFPE material is abundantly available in pathology archives. They are 
easy to handle and store but their research related applications remain limited (65-68). 
Recently, several studies have validated the use of FFPE tissue for DNA, RNA and 
protein related research (69, 70).  
A promising new alternative is HOPE fixation.  This fixation protocol may combine 
the benefits of both FFPE and fresh frozen material. The HOPE technique consists of 
a solution containing organic buffer, meant to serve as a protectant. Acetone acts as 
the dehydrating agent on the tissue, in combination with pure paraffin at 52-54°C 
melting temperature. The tissue is passed through the buffer to minimize degradation, 
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then dehydrated and fixed for long term use (71). HOPE fixed material has been used 
for several DNA and RNA based studies with promising results (71-73).  
With regards to CRPC samples, the availability of fresh frozen CRPC material is 
limited. This is mainly because patients with advanced PCa do not undergo biopsies 
of metastasis as part of routine medical care (69). And the availably CRPC samples 
are FFPE fixed and stored in pathology archives. Due to the fixation protocols, there 
are major limitations and hurdles faced in performing a broad spectrum of molecular 
analysis with such material.   
 
2.8 Next Generation Sequencing  
Next generation sequencing (NGS) has revolutionized science in the past few years. It 
has made a profound impact on the understanding of genetics and biology. In 
research, NGS has enabled the study of the complete human genome, exome, 
transcriptiome and epigenomics, unlike earlier methods, which allowed the study of 
only select regions of the genome, exome and transcriptome. The new generations of 
sequencing platforms have improved sequencing productivity at an exponential 
growth rate, enabling fast, cheap and accurate ways to analyze sequences. The well 
known sequencing platforms include the Roche 454 Genome Sequencer, the Illumina 
Genome Analyzer and the Life Technologies SOLiD System. Each system has 
advantages and disadvantages with reference to its wide range of applications.  
The Life Technologies SOLiD system functions on the principle of sequencing by 
ligation (74). It utilizes an average read length of 50 bp (base pairs). As FFPE samples 
are highly degraded, the short sequencing read length of 50 bp is optimal. In brief, a 
library of DNA/RNA fragments is prepared from the sample desired to be sequenced. 
The average size for SOLiD sequencing is 50-75 bp. These fragments are then 
17
	  	  	  
hybridized to beads. Each bead contains one fragment consisting of a universal P1 
adapter sequence. This is to maintain homogeneity within all the beads containing the 
same P1 adapter sequence.  This method uses the beads to generate amplified 
products by emulsion polymerase chain reaction (PCR) using the necessary PCR 
reagents. After the PCR reaction, the emulsion is broken and the beads containing 
amplified products are then immobilized on a substrate, a glass slide (Figure 7).  
 
Figure 7:  Emulsion PCR for the SOLiD platform  
An adaptor flanked shotgun library is amplified by PCR that includes beads in water in oil emulsion 
reaction. The primer goes and attaches to the surface of the bead. PCR amplicons are captured on the 
bead surface that can be enriched after breaking the emulsion. (adapted from Shendure et al. 2008). 
(75) 
 
The sequencing occurs on the glass slide where primers that hybridize to the P1 
adapter are used. To this reaction, dibase probes, probes consisting of two specific 
base pair combinations, compete for ligation to the primer sequence. Next, 
fluorescently labeled octamers are added to the mixture. Based on the position of the 
nucleotide in the octamer, a fluorescent signals is produced, determining the sequence 
of the fragment (Figure 8). Five sets of primers compete for each sequence. Through 
the sequencing process, to reduce the sequencing error, each base is read by two 
different primers in two independent ligation reactions. Therefore, the advantageous 
dual base encoding technology using dibase probes inherently corrects errors.  
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Figure 8:  SOLiD Sequencing  
Clonal amplification is performed on beads, to which fluorescently labeled octamers are added in 
cycles. After binding, cleavage occurs between position 5 and 6 and a new octamer is incorporated. 
This process is repeated in several cycles (adapted from Shendure et al. 2008). (75) 
 
Working with FFPE fixed tissue samples is a challenge due to cross linkage of 
biomolecules caused by the fixation protocols (76). Furthermore, nucleic acids are 
degraded into fragments. Due to above mentioned FFPE characteristics, using FFPE 
samples for NGS would require a platform that is capable of sequencing short 
fragments of DNA/RNA approximately 50-75bp in length. Therefore,, the ideal NGS 
platform is the SOLiD4 system, having an average read length of 50 base pairs and 
enabling an accurate capture of fragmented genomic DNA from FFPE tissues.   
 
2.9 Next Generation Sequencing Approaches 
Depending on the research question of interest, various approaches can be applied to 
NGS. Some of the most commonly used sequencing approaches have been described 
below: 
a) Genome sequencing- Genome sequencing refers to the sequencing of all 
chromosomes including the mitochondrial DNA of an organism. Due to the large 
amount of data that is generated through genome sequencing, efficient computational 
skills and large storage is required. The data generated from genome sequencing 
identifies somatic and autosomal variations in an individual. Unfortunately, whole 
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genome sequencing is currently an expensive tool, but with the introduction of new 
sequencing platforms in the market, the cost is drastically reducing (77). 
ii) Exome sequencing- The human exome makes up 1% of the genome and codes for 
proteins. The exome is composed of exons that are transcribed sequences that are part 
of the mRNA after the removal of introns. Previous studies have shown that the 
exome contains 85% of disease causing mutations in humans (78). There are 
approximately 180,000 exons in the human genome that are translated to 30 
megabases in length (79). The primary aim of performing exome sequencing is to 
identify the functional disease specific variation in humans. 
iii) Targeted resequencing- This method involves the sequencing of a particular 
region or gene of an individual’s chromosome. Genes identified through genome, 
exome and transcriptome sequencing are validated by targeted resequencing 
approaches with a high level of accuracy. Targeted resequencing is widely used in 
clinical settings to identify causative mutations within populations, or to identify low 
frequency SNVs, single nucleotide variations, or various structural variants 
 
2.10 Next Generation Sequencing and Prostate Cancer 
With reference to patient care, NGS paved way to personalized therapeutics medicine. 
Whole genome, exome and transcriptome sequencing have identified tumor specific 
mutations and genes that could serve as potential therapeutic targets for cancer 
therapy. The tremendous amount of data generated from sequencing has aided in 
understanding the development and progression of various cancers by identifying 
tumor specific genes that up regulate cancer specific pathways and processes. 
Additionally, worldwide collaborative efforts have been made in the form of the 
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International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas 
(TCGA) Project to study the genomic landscape of thousands of cancers (80, 81).  
Various studies have been aimed at understanding the molecular mechanism behind 
PCa initiation, development and progression through NGS technologies (69, 82-85). 
The aim of the studies is to capture a molecular signature for PCa at various stages to 
identify genes that have a potential role in tumorigenesis.  
The paradigm-shifting discovery of the TMRPSS2-ERG recurrent gene fusion in 
approximately 50% of primary PCa became a basis for stratifying patients into fusion 
positive and fusion negative patients. Unfortunately, its role as a therapeutic target is 
still not clear and is under development (26).  
In early 2011, in an attempt to perform an in-depth study on primary PCa, seven 
primary PCa samples were subjected to whole genome sequencing. Recurrent gene 
fusions involving CADM2 (cell adhesion molecule 2) and MAG12 (myelin associated 
glycoprotein) were reported to occur specifically in primary PCa, in addition to the 
TMPRSS2-ERG gene fusion (83). Exome sequencing on primary PCa also revealed 
the recurrent mutation of SPOP (speckle-type POZ protein), FOXA1 (forkhead box 
AQ), and MED12 (mediator complex subunit 12) (86). Furthermore, a deep 
mutational analysis was performed on mice xenografts of advanced and lethal PCa. 
TP53 (tumor protein p53), DLK2 (delta like 2 homolog), GPC6 (glypican 6) and 
SDF4 (stromal cell derived factor 4) were recurrently mutated in these samples (84).  
Patients suffering from CRPC, being the most lethal form of the disease, are in an 
urgent need to identify potential therapeutic targets to block or delay the progress of 
cancer. Various CRPC studies describing the structural and epigenetic changes, and 
the mutational landscape have reported alterations in the advanced form of the disease 
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(69, 82, 85). But, functionally, much remains to be done to validate the therapeutic 
targets and provide the commercially available inhibitors for patient care.  
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3. Aims of the Study 
 
Scientific Problem 
The number of PCa related deaths is increasing each year, which has resulted in an 
over-diagnosis or over-treatment of men suffering from the disease. A major 
challenge in CRPC is the limited availability of promising treatment options.  
Currently, the most effective treatment option is androgen deprivation therapy, but in 
due course of time, most men develop resistance to this hormonal approach.  
Therefore, there is an urgent need to identify biomarkers and potential therapeutic 
targets to delay or inhibit the progression of cancer from an indolent to a highly 
aggressive stage.  
Chromosome 8q amplification is a very common event in localized PCa. This 
chromosomal region consists of oncogenes such as cMYC, eIF3 and PSCA that play 
an active role in cancer initiation. Deletion of various tumor suppressors such as 
PTEN, NKX3.1 all together enhance cancer progression.  The discovery of the 
TMRPSS2-ERG rearrangement became a plausible basis for patient stratification but 
its function as a therapeutic target is under investigation.  
 
Aims 
The overall aim of this study is to decode the molecular and genetic alternations using 
novel high throughput sequencing approaches on a clinically well-defined cohort of 
hormone refractory prostate cancer (CRPC) patients to identify novel therapeutic 
targets. This aim was subdivided into three objectives- 
 
Objective I: Determining the DNA, RNA and protein integrity of fresh-frozen, FFPE 
and HOPE fixed tissue to identify the optimal tissue for sequencing and functional 
studies. 
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Objective II: Determining the sequencing efficiency of FFPE tissue, in comparison to 
fresh-frozen tissue, both obtained from the same patient, using the SOLiD4 
sequencing platform. 
 
Objective III: Identification of novel therapeutic targets for castration resistant 
prostate cancer by whole exome sequencing, and functional validation of the 
identified targets. 
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4. List of Abbreviations 
 
% 
 
percent 
AR androgen receptor 
bp base pairs 
BSA bovine serum albumin 
°C temperature in degree Celsius 
cDNA complementary DNA 
cMYC c-myc avian myelocytomatosis viral 
oncogene homolog 
CRPC castration resistant prostate cancer 
DAPI 4'-6-Diamidino-2-phenylindole 
DMEM dulbecco’s modified eagle medium 
DMSO dimethyl sulfoxide 
DNAse desoxyribonuclease 
dNTP deoxynucleotidetriphosphate 
EDTA ethylenediaminetetraacetic acid 
ERG v-ets erythroblastosis virus E26 oncogene 
homolog (avian) 
FBS foetal bovine serum 
FFPE formalin fixed paraffin embedded 
FISH fluorescent in situ hybridization 
g gram 
HE Hematoxylin and eosin 
HEPES 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
IHC immunohistochemistry 
kb kilobases 
kDa kilodalton 
L liter 
LN lymph node 
m milli 
M mol L-1 
µ micro 
mRNA messenger RNA 
NGS next generation sequencing 
NKX3.1 Homeobox protein NK-3 homolog A 
OD optical density 
PAGE polyacrylamide gelelectrophoresis 
PBS phosphate-buffered saline 
PCa prostate cancer 
PCR polymerase chain reaction 
PFA paraformaldehyde 
PTEN phosphatase and tensin homolog 
PTK2 protein tyrosine kinase 2 
PVDF polyvinylidene fluoride 
qRT-PCR quantitative real-time polymerase chain 
reaction 
RNase ribonuclease 
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x g centrifugal force 
SCNA somatic copy number alterations 
SDS sodium dodecyl sulfate 
siRNA short interference ribonucleic acid 
SNV single nucleotide variations 
 
SOLiD 
 
Sequencing by oligonucleotide ligation 
and sequencing 
Temed N,N,N’,N’-tetramethylethylendiamine 
TMA tissue microarray 
Tris Tris-(hydroxymethyl)-aminomethane 
UV ultra violet 
YWHAZ tyrosine 3-monooxygenase/tryptophan 5-
monooxygenase activation protein, zeta 
polypeptide 
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5. Materials 
 
 
5.1 Reagents 
 
Chemicals Manufacturer Location 
 
2-Propanol  AppliChem Gablingen 
Acetone AppliChem Gablingen 
Ammonium persulfate  Carl Roth Karlsruhe 
Ampicillin Sigma Aldrich Steinheim 
Bovine serum albumin standard Sigma Aldrich Steinheim 
CAS-Block Life Technologies Darmstadt 
Centromeric probe (Chr. 8) Metasystems Altussheim 
Chloramphenicol Sigma Aldrich Steinheim 
Cot Human DNA Roche  Mannheim 
DEPC, treated water  Carl Roth Karlsruhe 
Developer Fujifilm Düsseldorf 
Dextran Sulfate, Sodium Salt Merck Darmstadt 
di Natriumhydrogenphosphate Merck Darmstadt 
Digest-All 3 Invitrogen Karlsruhe 
Digoxigenin Roche Mannheim 
Dimethyl sulfoxide  Sigma Aldrich Steinheim 
Ethanol  AppliChem Gablingen 
Ethidium Bromide Sigma Aldrich Steinheim 
Ethylenediaminetetraacetic acid 
(EDTA) 
Sigma Aldrich Steinheim 
EtOH 100% Merck Darmstadt 
Fixer Fujifilm Düsseldorf 
Formamide Merck Darmstadt 
Glycerol  AppliChem Gablingen 
Glycine  Carl Roth Karlsruhe 
Glycogen, Ultra Pure Invitrogen Karlsruhe 
Hoechst 33342 Invitrogen Karlsruhe 
HOPE® Fixative System I Polysciences, Inc. Eppelheim 
HOPE® Fixative System II Polysciences, Inc. Eppelheim 
Human Cot-1 DNA Invitrogen Karlsruhe 
Hydrochloric acid  Merck Darmstadt 
Igepal CA 630 Sigma Aldrich Steinheim 
Illustra MicroSpin S-200 HR Columns GE Healthcare Munich 
Potassium chloride Merck Darmstadt 
Potassium hydrogen phosphate  Merck Darmstadt 
Laemmli loading buffer Carl Roth Karlsruhe 
LB- Agar Merck Darmstadt 
LB-Medium AppliChem Gablingen 
Lipfectamine siRNA MAX Invitrogen Karlsruhe 
Luria Broth - agar AppliChem Gablingen 
Luria Broth - medium AppliChem Gablingen 
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Methanol    AppliChem Gablingen 
Nonfat dried milk powder AppliChem Gablingen 
Normal Goat Serum Dianova Hamburg 
Page ruler protein ladder Thermo Scientific,  Karlsruhe 
Phosphatase inhibitor cocktail 2 and 3 Sigma Aldrich Steinheim 
Ponceau S    Sigma Aldrich Steinheim 
ProLong Gold antifade reagent with 
DAPI Invitrogen 
 
Karlsruhe 
Phenylmethanesulfonyl fluoride Sigma Aldrich Steinheim 
Protease inhibitor  Sigma Aldrich Steinheim 
Revertaid H-Minus First Strand cDNA 
Kit  Fermentas 
 
Karlsruhe 
RNAase zap Ambion Karlsruhe 
RNase A  AppliChem Gablingen 
Roti load 4x concentrate  Carl Roth Karlsruhe 
Sodium acetate Sigma Aldrich Steinheim 
Sodium azide  Carl Roth Karlsruhe 
Sodium chloride (NaCl)  Merck Darmstadt 
Sodium dodecyl sulfate  Carl Roth Karlsruhe 
Spot Light CISH Translocation Kit  Invitrogen Karlsruhe 
Streptavidin, Alexa Flour 594 conjugate 
2 mg/ml Invitrogen 
 
Karlsruhe 
Streptavidin, Rhodamine Red-x 
conjugate  Invitrogen 
 
Karlsruhe 
Tetramethylethylenediamine Carl Roth Karlsruhe 
Tris(hydroxymethyl)-aminomethane  Carl Roth Karlsruhe 
Tris(hydroxymethyl)-aminomethane  Carl Roth Karlsruhe 
Tween® 20  Merck Darmstadt 
Western Blot detection  
reagent 
GE Healthcare Munich 
Xylene  AppliChem Gablingen 
Xylol  ProLabo Cologne 
Yo PRO Invitrogen Karlsruhe 
β-mercaptoethanol  Alfa Aesar Karlsruhe 
 
5.2 Apparatus 
 
Apparatus Manufacturer Location 
 
Bacterial Shaker B. Braun Biotech 
International 
Melsungen 
BBD 6220 CO2 Incubator Thermo Scientific  Karlsruhe 
CovarisTM S2  Life Technologies 
GmbH 
Darmstadt 
ELISA reader Biotek Bad Friedrichshall 
Gel Doc X Biorad Munich 
IKA Vortex Genius 3 IKA Staufen 
Inverted Microscope Olympus Hamburg 
Light Cycler® 480 Real Time PCR Roche Mannheim 
28
	  	  	  
System 
Magnetic Shaker IKA Staufen 
Microtome Zeiss Oberkochen 
Millipore Milli Q Millipore Schwalbach 
Mini PROTEAN tetra electrophoresis 
system 
BioRad  Munich 
Multifuge 1L-R centrifuge Thermo Scientific Karlsruhe 
NanoDrop 2000c Thermo Scientific Karlsruhe 
Nikon Eclipse 80i Nikon Düsseldorf 
PCR system Applied 
Biosystems 
Darmstadt 
PCR work station Peqlab Erlangen 
pH meter PCE Deutschland Meschede 
PowerPac power supply BioRad Munich 
Semiautomatic tissue array instrument Beecher 
Instruments 
Sun Prairie, WI, 
USA 
Sorvall Legend Centrifuge Ependorf Hamburg 
Sterile Bench Scanlaf Denmark 
Thermo mixer Eppendorf Hamburg 
Thermocycler Applied 
Biosystems 
Darmstadt 
Trans blot SD semi dry electrophoretic 
Transfer Cell 
BioRad Munich 
Waterbath Memmert Schwabach 
Weighing Scale Thermo Scientific Karlsruhe 
Xcelligence Roche  Mannheim 
Zeiss, Oberkochen Imager.Z1 Zeiss Oberkochen 
 
 
5.3 Consumables 
 
Consumables Manufacturer Location 
 
1.5 ml tubes Fisher Scientific 
GmbH 
 Schwerte 
 
2 ml tubes Fisher Scientific 
GmbH 
 Schwerte 
 
6 well cell culture plates VWR International 
GmbH 
 Darmstadt 
12 well cell culture plates VWR International 
GmbH 
 Darmstadt 
24 well cell culture plates VWR International 
GmbH 
 Darmstadt 
96 well cell culture plates VWR International 
GmbH 
 Darmstadt 
15 ml falcon Labomedic GmbH 	  Bonn 
50 ml falcon Labomedic GmbH 	  Bonn 
15 ml falcon 
 
Labomedic GmbH 	  Bonn 
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25T cell culture flask VWR International 
GmbH 
Darmstadt 
75T cell culture flask Greiner Bio Frickenhausen 
Cell scraper TPP Switzerland 
Cryo tubes Labomedic GmbH Bonn 
PCR tubes Fisher Scientific 
GmbH 
Schwerte 
Pipette tips Nerbe Plus Winsen/Luhe	  
Sterile filter 0.2 µm VWR International 
GmbH 
Darmstadt 
 
5.4 Kits 
 
Kits Manufacturer Location 
 
Agencour AMPure XP Beckman Coulter Krefeld 
Agilent RNA 6000 nano kit Agilent 
Technologies 
Ratingen 
Agilent Sure Select Agilent Waldbronn 
BCA protein assay kit Thermo Scientific Karlsruhe 
Bio Prime Kit Life Technologies Darmstadt 
Cell proliferation kit I Roche Mannheim 
Library Column Purification Kit Applied 
Biosystems 
Darmstadt 
LightCycler 480 ProbesMaster Roche Mannheim 
Plasmid maxi kit Qiagen Hilden 
Plasmid mini kit Qiagen Hilden 
Recover All Extraction Kit Life Technologies Darmstadt 
Repli-g Mini Kit Qiagen Hilden 
RNeasy mini kit Qiagen Hilden 
RNeasy mini kit Qiagen Hilden 
SuperScript VILO cDNA synthesis kit Life Technologies Darmstadt 
TAE 226 inhibitor Novartis Switzerland 
 
5.5 Cell Culture Reagents 
 
Cell culture reagents Manufacturer Location 
 
Dimethylsulphoxide (DMSO) PAN Biotech Aidenbach 
F12 Nutrient Media Life Technologies Darmstadt 
Fetal calf serum (FCS) PAA Cölbe 
HEPES PAN Biotech Aidenbach 
L-Glutamine PAN Biotech Aidenbach 
Non essential amino acids (NEAA) Life Technologies Darmstadt 
Penicillin/Streptomycin PAA Cölbe 
Phosphate buffered saline (PBS) Life Technologies Darmstadt 
RPMI 1640 Life Technologies Darmstadt 
RPMI 1640+ GLutamax Life Technologies Darmstadt 
Trypsin-EDTA Life Technologies Darmstadt 
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5.6 Cell Lines 
 
Cell line Description Manufacturer 
 
Du-145 Brain metastasis derived 
from prostate cancer  
ATCC 
LNCaP Lymph node metastasis 
derived from prostate 
cancer  
ATCC 
PC-3 Bone metastasis derived 
from prostate cancer 
ATCC 
VCaP Bone metastasis derived 
from prostate cancer 
ATCC 
 
5.7 Antibodies 
 
Antibodies Manufacturer Location 
 
14-3-3 ζ (C-16): sc-1019 
polyclonal 
Santa Cruz Heidelberg 
Goat anti mouse HRP Sigma Aldrich Steinheim 
Goat anti rabbit HRP Sigma Aldrich Steinheim 
GOLPH2 Antibody 
(5B10) 
Abnova Heidelberg 
Mouse anti β-actin Sigma Aldrich Steinheim 
p63 Antibody (4A4) Dako Belgium 
Prostate Specific Antigen 
Antibody (35H9) 
Novocastra UK 
Purified Mouse Anti-FAK 
monoclonal 
BD Transduction 
Laboratories 
Heidelberg 
Purified Mouse Anti-
Human FAK (pY397) 
monoclonal 
BD Transduction 
Laboratories 
Heidelberg 
 
5.8 Primers 
 
Primers for qPCR Sequence 
 
β-actin forward 5’GCACCCAGCACAATGAAGA3’ 
β-actin reverse 5’CGATCCACACGGAGTACTTG3’ 
YWHAZ forward 5’GATCCCCAATGCTTCACAAG3’ 
YWHAZ reverse 5’TGCTTGTTGTGACTGATCGAC3’ 
PTK2 forward 5’TGAGGGAGAAGTATGAGCTTGC3’ 
PTK2 reverse 5’TTGGCAAATAACGAATTCTCAA3’ 
GAPDH forward 5’GAGTCAACGGATTTGGTCGT3’ 
GAPDH reverse 5’TGGGATTTCCATTGATGACA3’ 
GAPDH probe 5’FAM-CAATGACCCCTTCATTGACC-TAMRA-3’ 
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β-actin forward 5’AGAGCTACGAGCTGCCTGAC3’ 
β-actin reverse 5’AGTACTTGCGCTCAGGAGGA3’ 
β-actin probe 5’FAM-CTGTACGCCAACACAGTGCT-TAMRA-3’ 
TBP forward 5’GCCCGAAACGCCGAATAT3’ 
TBP reverse 5’CCGTGGTTCGTGGCTCTCT-3’ 
TBP probe 5’FAM-ATCCCAAGCGGTTTGCTGCGG-TAMRA-3’ 
 
Primers for PCR Sequence 
 
TBXAS1 forward 5’GCCCGACATTCTGCAAGTCC3’ 
TBXAS1 reverse 5’GGTGTTGCCGGGAAGGGTT3’ 
RAG1 forward 5’TGTTGACTCGATCCACCCCA3’ 
RAG1 reverse 5’TGAGCTGCAAGTTTGGCTGAA3’ 
AF4 reverse 5’CCGCAGCAAGCAACGAACC3’ 
AF4 forward 5’GCTTTCCTCTGGCGGCTCC3’ 
AF4 reverse 5’GGAGCAGCATTCCATCCAGC3’ 
AF4 forward 5’CATCCATGGGCCGGACATAA3’ 
PLZF forward 5’TGCGATGTGGTCATCATGGTG3’ 
PLZF reverse 5’CGTGTCATTGTCGTCTGAGGC3’ 
 
5.9 siRNA 
 
siRNA Sequence 
 
YWHAZ target sequencing 5’AAAGUUCUUGAUCCCCAAUGC3’ 
Scrambled sequence 5’-CAG-UCGCGUUUGCGACUGG3’ 
YWHAZ pooled 
sequencing 
5’GCUUGGUAUUCAUUACUUC3’ 
5’GAAUCAUACCCCAUGGAUA3’ 
5’UCUGUAUGUUCUAUUGUGC3’ 
5’UCUUGAUCCCCAAUGCUUC3’ 
 
5.10 Buffers and Solutions 
 
Buffers and solutions  
 
 
Ripa-lysis buffer 
1%  Igepal CA 600 
0.5% Na-deoxycholate 
10%SDS 
0.25 M EDTA 
PBS 
TBS-T (pH 7.5) 50 mM Tris-Cl 
150 mM NaCl 
0.05% Tween 20 
Transfer buffer (pH 8.3) 250 mM Tris-Cl 
1.92 M Glycine 
Running buffer (pH 8.3) 250 mM Tris-Cl 
1.92 M Glycine 
1% SDS 
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20x SSC (pH7.0) 3 M NaCl 
300 mM Tridsodium citrate 
Cot 1 solution 1.5 µg/µl cot-1 in hybridization buffer 
1x PBS (pH 7.4) 137 mM NaCl 
10 mM Phosphate 
2.7 mM KCl 
TE (pH 8.0) 10 mM Tris 
1 M EDTA 
PI/RNase A  50 mg/ml Propidium Iodide 
0.5% Glucose in 1x PBS 
Stacking Gel buffer (pH 
6.8) 
125 mM Tris-Cl 
0.1% SDS 
Separating Gel Buffer (pH 
8.8) 
375 mM Tris-Cl  
0.1% SDS 
2 x SSC 0.3 M NaCl 
7.5mM Sodium citrate 
Hypotonic Potassium 
Chloride (0.075M) 
0.56 g 
100 ml dH20 
Hybridization Buffer 10% Formamide 
10% Dextran sulphate sodium 
in 2x SSC 
 
5.11 BAC Clones 
 
BAC clones Clone Manufacturer 
 
ERG centromeric RP11-24A1 Invitrogen 
ERG telomeric RP11-372017 Invitrogen 
Centromeric Clones Chr. 5,8,10,16,X Invitrogen 
PTEN CTD-2267G16 Invitrogen 
cMYC CTD-3056O22 Invitrogen 
AR RP11-479J1 Invitrogen 
NKX3.1 RP11-213G6 Invitrogen 
YWHAZ CTD-2310E8 Invitrogen 
PTK2 RP11-188K5 Invitrogen 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
33
	  	  	  
6. Methods 
 
6.1 Next generation sequencing (SOLiD4) 
 
DNA Extraction 
A 3 µm biopsy needle was used to punch three cores from FFPE, HOPE and fresh-
frozen tissues for DNA extraction. Extraction was performed using the RecoverAllTM 
total nucleic acid isolation kit for FFPE and HOPE fixed tissue. Fresh frozen tissue 
was extracted using the Phenol:Chloroform:Isoamylalcohol (PCI) (25:24:1) method. 
This method, upon centrifugation at 16200 x g (Multifuge 1L-R, Thermo Scientific, 
Germany) creates an upper aqueous phase, containing nucleic acids, and a lower 
organic phase, containing proteins. DNA was obtained in the aqueous phase in the 
absence of guanidine thiocyanate. Precipitated DNA was resuspended in 50 µl of 
distilled water and stored at -20°C and used for further applications. 
 
DNA Concentration and Integrity 
DNA concentration of the samples was determined using the NanoDropTM. This 
instrument is capable of providing a 260/280 ratio, and for DNA a ratio of 
approximately 2 is considered pure. In parallel a 2100 Bioanalyzer was also used for 
sizing, quality control and quantification of the DNA.  This instrument is based on a 
lab-on-chip technology and is capable of quantifying the samples and checking for its 
integrity by displaying specific peaks. The Bioanalyzer works on the principle of 
capillary electrophoresis, where in the presence of high electric fields, fast separation 
of the sample occurs. Upon separation, the computer generates an electrogram 
providing provides a precise quantitative analysis of the sample. Only a minute 
amount of sample (1 µl ) is needed for the analysis. 
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DNA Sample Shearing 
Upon qualification and quantification of the samples, they were sheared using the 
CovarisTM S2 (Life Technologies GmbH, Darmstadt, Germany) to produce fragments 
of 150-180 bp. For sequencing purposes, a minimum of 1.5 µg of DNA is required. 
The Covaris instrument uses acoustic energy to shear the DNA samples into small 
fragments for further amplification and sequencing. Ultrasound is applied to the 
samples for shearing generating fragments.   
The following program was used for the shearing- 
Setting Value 
Number of Cycles 6 
Bath Temperature 5°C 
Bath Temperature Limit 8°C 
Mode Frequency sweeping 
Water Quality Testing Function Off 
Duty Cycle 20% 
Intensity 5 
Cycles per Burst 200 
Time 60 seconds 
 
Sample Purification and Amplification 
After shearing, the samples were subjected to end repair and purified using the SOLiD 
Library Column Purification Kit (Applied Biosystems, Darmstadt). The appropriate 
fragments selected using the Agencourt AMPure XP (Beckman Coulter, Krefeld) 
beads and amplified. The PCR amplification mix consisted of the following 
components– 
Setting	   Value	  
Adapter ligated library 15 µl  
Nuclease free water 15.5 µl 
SureSelect AB pre-capture primers 8 µl 
5x Herculase II reaction buffer 10 µl 
100mM dNTP mix 0.5 µl 
Herculase II fusion DNA polymerase 1 µl 
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The PCR protocol- 
 
Step Temperature Time 
Step 1 98°C 2 min 
Step 2 98°C 30 sec 
Step 3 54°C 30 sec 
Step 4 72°C 1 min 
Step 5  Repeat step 2 through 4 for 
6 cycles 
Step 6 72°C 10 min 
Step 7 4°C Hold 
 
 
Hybridization to the Library 
The DNA fragments that were hybridized to the AMPure beads and eluted post 
amplification, were subjected to adaptor ligation to P1 and P2 adaptors.  These 
adaptor ligated were then hybridized to the Agilent SureSelect capture library 
(Agilent, Waldbronn). The SureSelect Target Enrichment allows capture of all 
targeted exomes from the DNA sample of interest. This system uses 120-mer baits to 
capture regions of the exome from the fragmented DNA sample. Targeted regions are 
selected using streptavidin magnetic beads and quantified using the Agilent 
Bioanalyzer DNA 100 and high sensitivity DNA chip.  
 
Templated Bead Preparation 
After library construction, each library is clonally amplified on P1 DNA beads using 
oil emulsion PCR known as the EZ Bead system. The random fragments of the 
sample are placed on the beads in oil phase. This PCR occurs in the oil phase 
immobilizing the copies for sequencing using the SOLiD4. 
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Figure 9:  SOLiD Sequencing pipeline overview.  
 
6.2 Fixation protocols (Fresh frozen, FFPE and HOPE) 
Fresh PCa tissues were cryopreserved by freezing in liquid nitrogen for up to 3 
minutes and then storing in -80°C. FFPE fixation was performed by fixing in 10% 
neutral buffered formalin and embedded in paraffin. For HOPE fixation of tissues, 
tissue samples were dipped in HOPE® I solution at 0-4°C for 12-72 hours. This was 
following by the removal of the HOPE® I solution and the addition of the ice cold 
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HOPE® II and acetone solution for two hours. These steps were repeated twice. Low 
melting paraffin was then melted onto the tissue in a  block cassette an stored at 4°C. 
 
6.3 Fluorescent In Situ Hybridization 
Tissue Microarray Construction  
Tissue microarray slides were constructed from FFPE PCa samples. The tissue 
microarrays contained samples of a total of 137 localized PCa cases, 105 primary PCa 
with 71 corresponding lymph node metastasis, and 39 cases of CRPC. Each case was 
represented in triplicates and each core was 0.6 mm in diameter.   
 
FISH Assays 
A fluorescence in-situ hybridization (FISH) assay was used to detect the genes that 
were amplified/deleted or rearranged at the chromosomal level. FISH uses a technique 
to identify the presence or absence of specific DNA sequences on the chromosomes. 
Fluorescently labeled probes that are complementary to the regions of interest were 
used to detect chromosomal alterations (Figure 10). The fluorescent signals were then 
detected using a fluorescence microscope (Zeiss, Jena, Germany) to detect the emitted 
fluorescence of the gene of interest.   
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Figure 10:  Fluorescent In Situ Hybridization (FISH).   
Fluorescently labeled DNA probes, complimentary to the gene of interest, hybridize to single stranded 
DNA. The fluorescence is then detected using a fluorescence microscope. This method is used to detect 
regions of chromosomal amplification, deletion or rearrangement (87). 
 
Deparaffinized sections were pre-treated with a 100 mM Tris and 50 mM EDTA 
solution at 92.8C° for 15 min. and digested with Digest-All III (dilution 1:2) at 37°C 
for 14 min.; FISH probes were denatured at 73°C for 5 min. and immediately placed 
on ice. Subsequently, the tissue sections and FISH probes were co-denatured at 94°C 
for 3 min. and hybridized overnight at 37°C. Post hybridization washing was done 
with 2x SSC at 75°C for 5 min, and the fluorescence detection was carried out using 
streptavidin-Alexa-594 conjugates (1:200 in hybridization buffer) and anti-
digoxigenin-FITC (dilution 1:200 in hybridization buffer). Slides were then 
counterstained with 4’,6-Diamidin-2’ phenylindoldihydrochloride (DAPI) and 
mounted.  
The samples were analyzed under a 63x oil immersion objective using a fluorescence 
microscope (Eclipse 80i, Nikon, Germany) equipped with appropriate DAPI, FITC, 
!"#$%&'()&
!"#$%&'()&
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TRITC and Alexa 594 Flour filters, a charge-coupled device camera and the FISH 
imaging and capturing software Metafer 4 (Metasystems, Altlussheim, Germany). 
Three experienced evaluators did the evaluation of the tests independently. At least 
100 nuclei per case were evaluated.  
 
Preparation of Metaphase Spreads for Adherent Cells 
In order to assess the specificity of the FISH probes, the probes were tested on 
metaphase spreads. 5 ml of heparinized human blood was cultured in the incubator 
(BBD 6220 CO2 Incubator, Thermo Scientific, Germany) at 37°C for three days and 
were then treated with colcemid (0.1 µg/ml) for 4 h. Colcemid disrupts the spindle 
apparatus and the cells are maintained in the metaphase. The cells were then lysed 
using a hypotonic potassium chloride solution (0.075 M). The cells were washed three 
times with ice cold methanol:acetic acid solution (2:1).  
 
6.4 Cell Culture 
Cell Lines  
LNCaP, VCaP, PC-3 and DU-145, immortalized PCa cell lines, obtained from the 
American Type Culture Collection (ATCC) were cultured according to the ATCC, 
USA online instructions. LNCaP and DU-145 cells were cultured in RPMI-1640 
media with L-glutamine and without Phenol Red (Gibco, UK), supplemented with 1% 
penicillin/streptomycin, 10% FBS and 25 mM HEPES. PC-3 cells were grown in 
F12K nutrient mixture containing L-glutamine (Gibco, UK), supplemented with 1% 
penicillin/streptomycin and 10% FBS. VCaP cells were grown in DMEM-F12 
nutrient mixture (Gibco, UK) supplemented with 1% penicillin/streptomycin, 10% 
FBS and 1% L-glutamine. 
40
	  	  	  
 
Cell Culture Conditions 
All cells were split and fed under a sterile laminar hood (Sterile Mars Safety Class 2, 
Scanlaf, Denmark) The cells were grown incubated in an incubator in humidified 
environment at 37°C with 5% CO2 (BBD 6220 CO2 Incubator, Thermo Scientific, 
Germany).  
 
Cell Passaging 
All cell lines were passaged upon achieving 80% confluency. The T-75 cell culture 
flasks were trypsinized using 1.5 ml (0.25% Trysin-EDTA) and incubated for 3 min at 
37°C (BBD 6220 CO2 Incubator, Thermo Scientific, Germany). The cells were then 
collected and centrifuged at 3200 x g for 5 min (Multifuge 1L-R, Thermo Scientific, 
Germany). The cell pellet was resuspended in PBS and the centrifugation was 
repeated. The supernatant was aspirated and new media was introduced, the cells were 
then seeded into new tissue culture flasks. 
 
Cell Counting 
The cells were trypsinized as described above. The pellet was then dissolved in a 
given volume of media. 10 µl of cells were added to 90 µl of Trypan blue solution 
(0.4% sterile filtered prepared in 0.81% sodium chloride and 0.06% potassium 
phosphate) (Sigma Aldrich, Germany). The cells were then counted using a Neubauer 
counting chamber. The average of four squares was taken to determine the 
concentration of cells. 
Concentration= Number of cells x 10,000/ Number of squares x dilution  
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Freezing and Thawing Cells 
Cells were trypsinized as described above. The cells were then centrifuged (Multifuge 
1L-R, Thermo Scientific, Germany) at 3200 x g for 5 min and the supernatant 
discarded. Freezing medium consisting of 10% DMSO and 10% FBS was added to 
the cells in cryo vials. Each vial had an end volume of 1ml. The vials were placed in -
80°C overnight and then in liquid nitrogen for long-term storage. 
For thawing, cells were slowly allowed to thaw in a 37°C water bath until the sides 
are thawed but the center remains frozen. Then the cells were diluted by adding 1ml 
of media to the vial. Cells were centrifuged at 3200 x g for 5 min and washed with 
PBS. New medium was added and the cells were seeded.  
 
6.5 Protein Analysis 
Protein Isolation 
Cells were trypsinized and washed with PBS. The pellet was then suspended in 
solution containing 100µl of RIPA-buffer, protease inhibitor, PMSF and phosphatase 
inhibitor (1:100). The cells were allowed to lyse on ice for 2 hours, after which they 
were centrifuged (1L-R, Thermo Scientific, Germany) at 13800 x g for 20 min at 4°C. 
The supernatant was transferred to a new tube 1.5 ml Eppendorf tube and stored at -
20°C.  
 
Protein Concentration 
Protein concentration of the sample was determined using the BCA protein assay kit 
according to manufacturers’ protocol. The principle of this kit is based on the 
formation of a Cu+2 protein complex under alkaline conditions. This is followed by 
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the reduction of Cu+2 to Cu+1. The extent of reduction is based on the amount of 
protein present.  BCA forms a purple color in the presence of Cu+1 in alkaline 
solutions. Its absorbance is read at 562 nm. A standard curve was also prepared using 
protein concentrations ranging from 0-1.2 mg/ml. 
 
SDS-PAGE and Western Blot 
Protein lysates, varying from 20 µg – 50 µg were used for Western blot analysis. 
Proteins were separated based on molecular weight using a 12% SDS-polyacrylamide 
gel for approximately 1.5 hours at 150 V (200 mA).  
The proteins were transferred to a nitrocellulose/PVDF membrane using the semi-dry 
procedure (1 h, 16 V). After the transfer, a Ponceau S staining was performed to 
detect protein loading and washed with TBS-T, the membrane was then blocked with 
TBST 5% skim milk powder, diluted in TBS-T. Incubation with the respective 
primary antibody and its recommended dilution was done overnight at 4°C. 
The following day, the membranes were incubated with the corresponding secondary 
antibody, conjugated to horseradish peroxidase for 1 h at room temperature. 
Visualization of the protein bands was carried out with the enhanced 
chemiluminescence (ECL plus) detection system (GE Healthcare, Munich). The ECL 
reagent contains luminol substrate and peroxide solution. The ECL is based on the 
emission of light during the horseradish peroxides and hydrogen peroxide catalyzed 
oxidation of luminol. Signal intensities for the Western blots were measured using the 
Scion Image software (Scion Corp., MD, USA). Protein yield was calculated using 
the AxioVision Rel 4.8 (Carl Zeiss Imaging Solutions GmbH, Göttingen, Germany). 
The protein yield was calculated using the following formula- 
Total protein amount/(area ∗ section thickness ∗ number of sections) = Xµg/mm3 
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6.6 Functional Assays 
RNA Extraction 
The RNA extraction on the cells lines was performed using the RNeasy kit (Qiagen, 
Hilden) according to the manufacturers protocol. The cells were lysed in an 
appropriate volume of the lysis buffer RLT containing 1% β-mercaptoethanol. RNA 
was then eluted using distilled water. The RNA concentration was measured by 
calculating its optical density which was measured with a photometer at λ=260 nm. It 
is known that RNA with an OD260 of 1 corresponds to a concentration of 40 µg/ml. 
The Agilent Bioanalyzer was also used to assess the integrity of the RNA. The quality 
of the RNA was verified by the identification of the ribosomal RNA (18S and 28S). 
 
Synthesis of cDNA 
RNA is converted to cDNA to detect the amount of mRNA in the samples. After 
extraction of total RNA, reverse transcription was performed by using the Super 
Script Vilo cDNA synthesis Kit (Life Technologies, Germany) according to the 
manufacturers protocol. The amount of RNA was adjusted to 200 ng per reaction 
(total volume: 20 µl). The reaction occurred under the following profile: 25°C/10 min; 
42°C/60 min; 85°C/5 min. 
 
Semi quantitative Real-Time PCR 
Each sample was tested in triplicates.  The PCR was performed in the Roche LC480 
Light Cycler (Roche, Basel) under the following conditions: 95°C for 10 min, 57°C 
for 30 sec, 72°C for 1 sec and 40°C for 30 sec. The threshold cycle (Ct) values were 
normalized using the housekeeping gene β-actin. Water was taken as a negative 
control. 
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The principle behind the Light Cycler assay is the measurement of fluorescence. A CT 
value is determined, this value denotes the first detection of fluorescence after 
crossing the threshold that has been set by the user. The normalized CT values, also 
called ∆CT, are calculated the following way: 
 
Formula 1: 
∆CT= CT (target gene) - CT (housekeeping gene) 
 
The lower the CT value the higher the mRNA expression, because less cycles are 
needed to reach the specific threshold in the intensity of the fluorescence. The 
difference of one CT value between two samples corresponds to double of the amount 
of RNA (cDNA), when the efficiency of the primers is assumed to be 100%. Since the 
primer efficiency was assumed to be 100%, the following calculation was carried out 
to calculate the gene expression: 
 
Formula 2: 
Gene Expression = 2-∆CT 
 
Mutational Analysis 
Mutational analysis was performed by Sanger sequencing. Briefly, DNA extraction 
was performed using the phenol-chloroform method, as mentioned above.  Mutational 
analysis was performed by Sanger sequencing using specific primers or the genes of 
interest.  DNA was denatured in to single strands allowing the primers to anneal to the 
template strand. Upon attaching of the primer, strand elongation takes place in the 
presence of fluorescently labeled nucleotides (ddNTPs) and normal nucleotides 
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(dNTPs). The sequencing is run in four different sequencing reactions. When the 
fluorescently labeled ddNTP is incorporated, strand elongation is terminated, and a 
light is emitted. This emitted fluorescence was then recorded on a chromatogram with 
fluorescent peaks.   
 
Gene Knockdown 
PC-3 cells were transfected using Lipofectamine RNAiMAX (Invitrogen, USA) 
according to the instructions of the manufacturer. The siRNAs were added at a 
concentration of 100 nmol/L. Western Blots were performed as described above to 
detect the efficiency of the knockdown using antibodies specific to the protein. 
Similarly, β-actin was used as a control for protein loading. 
 
Inhibition Assay 
PC-3 cells were treated with TAE-226, a pharmacological PTK2 (Protein Tyrosine 
Kinase 2) inhibitor (Novartis, Switzerland) at various concentrations. The inhibitor 
was dissolved in dimethyl sulfoxide (DMSO) and stored at 4-8°C. Western Blot was 
performed using specific antibodies to detect the targeted proteins, in parallel, β-actin 
was used as a control. 
 
Proliferation Assay  
Cell proliferation assays were performed on the PC-3 cells treated with the 
pharmacological TAE226 inhibitor or after YWHAZ knockdown experiments using a 
cell proliferation MTT Kit (Roche, Switzerland) according to the manufacturers 
protocol.  A total of 5000 cells were seeded in a 96 well plate, followed by treatment 
with inhibitor/siRNA. Cell proliferation was determined after 24, 48 and 72 hrs of 
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incubation. This calorimetric assay is based on the reduction of 3-(4,5-dimethythiazol-
2-yl)-2,5-diphenyl tetrazolium bromide (MTT) by mitochondrial succinate 
dehydrogenase. Viable cells produce formazan as a product. The formazan is then 
solubilized with an organic solvent and released. The absorbance was read at 595 nm.  
 
Cell Migration Assay 
Boyden Chamber migration assays were performed using the 24-well Matrigel 
invasion chambers with 8 µm polycarbonate filters that are coated with Matrigel (BD 
Bioscience, USA). 1x105 cells were placed in the Matrigel pre-coated upper chamber 
insert (BD Biosciences, USA) with media containing 2% FBS. The lower chamber 
was filled with media containing 10% FBS. The principle is the movement of cells 
moving from the upper chamber to the lower chamber as cells are attracted to media 
containing 10% FBS.  The cells were incubated for 24 hrs, after which the membrane 
was removed from the insert and stained with hematoxylin (Fulda, Germany). The 
invading and migrating cells were counted in three different fields and the two-sided 
unpaired T-test was used to determine statistical significance.   
 
Apoptosis Assays 
Cells were grown for 24, 48 and 72 hours with the pharmacological TAE226 inhibitor 
(Novartis, Switzerland) and stained with Hoechst 33342 and YO-PRO-1, as described 
by the manufacturers protocol. YO-PRO-1 enters the apoptotic cells and stains them. 
Hoechst 33342 brightly stains the condensed chromatic of apoptotic cells and dimly 
stains the normal living cells. Cell treated with Doxorubicin (Sigma Aldrich, 
Germany) at a 10 µM concentration was used as a positive control, and untreated cells 
were used as a negative control. Data acquisition was performed on an LSR II flow 
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cytometer (BD Biosciences, Germany). FlowJo software was used to perform further 
data analysis (TreeStar, US).  
 
Cell Cycle Arrest 
Cells treated with the pharmacological TAE226  inhibitor were fixed in 70% ethanol 
and stained with PI/RNase A solution (50 µg/ml of RNase A (Sigma, USA), 50 mg/ml 
of propidium iodide (Sigma, Germany)) dissolved in sample buffer containing 0.5% 
glucose in 1x PBS. The FACS analysis was performed using a Becton Dickinson 
FACSCalibur to determine DNA content. The data analysis software FlowJo 
(TreeStar, US) was used for further analysis.  
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7. Results 
7.1 Objective I: Determining the DNA, RNA and protein integrity of fresh-
frozen, FFPE and HOPE fixed tissue to identify the optimal tissue for sequencing 
and functional studies. 
PCa tissue is commonly available in three forms: fresh frozen, FFPE and HOPE fixed 
respectively. For sequencing and molecular based studies, it is necessary to determine 
the DNA, RNA and protein integrity of each fixation protocol for downstream 
applications.  
This study was performed on prostatectomy samples obtained from 10 patients who 
had undergone a radical prostatectomy at the University Hospital of Tuebingen. An 
in-depth histological examination was performed on all specimens prior to DNA and 
RNA extraction. This histological examination involved a hematoxylin and eosin 
staining (HE staining) performed on the frozen tissue to identify regions of tumor for 
DNA/RNA/protein analysis. Upon identification and isolation of the cancer region, 
the frozen sample was cut into three equal sizes and subsequently fixed using the 
conventional FFPE protocol, HOPE-fixation and cryo conservation methods. 
 
A. Histological and Morphological Analysis 
Upon the FFPE, HOPE and cryopreservation of each sample, they were all subjected 
to a histological and morphological analysis. The histological and morphological 
analysis for each sample was performed by HE staining, immunohistochemistry 
(IHC) analysis and FISH analysis.  
The samples were firstly, subjected to an HE staining. HE staining detects the nuclei 
of the cells and stains them blue due to the hemalum dye and stains the eosinophilic 
structure (such as proteins) in shades of red and orange using the eosin dye. This 
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method was used to distinctly identify the cell membranes and nuclei in each fixation 
protocol. With reference to histomorphology, HOPE specimens often displayed a 
FFPE like morphology (Figure 11 A) where the nucleus and the cells were distinctly 
stained with no interference and no or little background. The tumor regions were 
clearly identified in both FFPE and HOPE fixed specimens. Fresh frozen specimen, 
on the other hand, exhibited typical freeze related artefacts, which included a distorted 
morphology and interfering background.  
The samples were then subjected to IHC staining using the p63 antibody. The p63 is a 
homolog of the tumor suppressor p53. The antibody is known to stain the basal cells 
of the prostate gland.  A variation in the manufacturer’s protocol was required for the 
IHC staining of HOPE samples, which required no epitope retrieval and a brief 
proteinase treatment for better signal quality. Both the FFPE and fresh frozen samples 
possessed benign and infiltrating PCa glands while the HOPE specimen depicted 
tumor glands and an intraductal spread of PCa (Figure 11 B). The p63 antibody 
stained the basal cells of the FFPE and frozen specimen, and in the HOPE specimen, 
the antibody stained both the basal cells with intraductal spread. The antibody binding 
specificity and signal strength were comparable in all three fixation protocols. 
Unfortunately, the histomorphologic quality was inferior in the fresh frozen samples 
with interfering background due to freezing (Figure 11 B). 
Thirdly, a FISH analysis was performed using probes specific for the TMPRSS2-ERG 
rearrangement. While performing a FISH analysis, the nucleus of the cell is distinctly 
visible due to DAPI and similarly, depending on the extent of degradation of the 
DNA, the FISH probes attach to the targeted regions of interest. The fresh frozen 
specimen exhibited specific signals but a typical freeze related clumping of cells was 
observed. The nuclei of the cells did not possess a clear morphology. On the other 
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hand, the FISH, using probes specific for the TMPRSS2:ERG gene fusion, on both 
FFPE and HOPE fixed PCa tissue showed distinctly specific signals and clear nuclear 
morphology (Figure 11 C).  
 
Figure 11:  Morphological quality comparison between FFPE, HOPE, and fresh-frozen 
specimens.  
(A) Representative HE stained sections of FFPE, HOPE, and fresh frozen material.  
(B) Representative p63 antibody IHC of FFPE, HOPE, and fresh frozen material.   
(C) Representative Fluorescence in-situ hybridization of ERG rearrangement on FFPE, fresh frozen 
and HOPE tissue sections (Braun and Menon et al., 2011). (88) 
 
B. DNA Integrity Analysis 
DNA extraction was performed from the FFPE, HOPE-fixed and fresh frozen 
specimen from six patient samples. To assess the DNA integrity, a PCR analysis was 
performed using a set of five primers yielding five different amplicons. Genes of 
varying amplicon sizes were chosen to determine the extent of DNA fragmentation 
A.
FFPE      FrozenHOPE
B.
C. 
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induced by the fixation protocols. The genes included human thromboxane synthase 
gene- 100bp (TBXAS1, exon 9; Chr7q34-35), human recombination activating gene- 
200bp (RAG1, exon 2; Chr11p13), human promyelocytic leukemia zinc-finger gene- 
300bp (PLZF, exon 1; Chr11q23.1), and human AF4 gene- 400 and 600bp (exon 3; 
and exon 11; Chr5q31). 100 ng/µl of DNA was introduced into each reaction for the 
analysis. All six samples showed distinct bands ranging from 100-400bp. The 600bp 
band was absent or hardly visible in the FFPE samples (Figure 12). 
 
Figure 12:  DNA integrity of FFPE, HOPE, and fresh-frozen tissues. 
(A-C) Agarose gels showing PCR products ranging from 100-600bp from six FFPE, HOPE and fresh 
frozen patient samples (Braun and Menon et al., 2011). (88) 
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C. RNA Integrity Analysis 
RNA extraction was performed on the FFPE, HOPE fixed, and fresh frozen samples 
from six patients, followed by a real time RT-PCR. The RNA was then reverse 
transcribed to produce cDNA, which was then used to determine the Ct value for 
comparison. The real time RT-PCR was performed using three housekeeping genes, 
TBP (73bp), GAPDH (201bp) and ß-actin (300bp) namely. The amplicons of all three 
house-keeping genes were of varying sizes in order to determine the degree of RNA 
fragmentation induced by the fixation protocols. The results of the RNA integrity 
analysis showed that the fresh frozen specimen had the lowest average Ct value 
(Figure 13). This is primarily due to the lack of fixative interference in these tissues.  
 
Figure 13: Representative real-time RT-PCR targeting TATA-binding-protein (TBP, 73bp) in 
FFPE, HOPE, and fresh-frozen tissues.  
The threshold value of HOPE fixed specimens was comparable to that of the fresh-frozen specimen 
(Braun and Menon et al., 2011). (88) 
 
The average Ct threshold HOPE values for TBP, GAPDH and ß-actin were 29.2, 27.8, 
and 27.6 respectively. The average Ct threshold FFPE values for TBP, GAPDH and ß-
actin were 33.2, 34.5, and 35.5, respectively. The average Ct threshold of fresh-frozen 
specimens values for TBP, GAPDH and ß-actin were 27.1, 26.4, 25.8 respectively 
(Table 1).  Each experiment was performed in triplicates and repeated three times. 
The differences in the average Ct values were statistically significant.  
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Ct	  values	  for	  TBP	  
mRNA	  expression	  	   	   	  
FFPE	   HOPE	   Native	  
29.9	   27.15	   25.5	  
31.89	   29.18	   27.2	  
34.8	   29.8	   28.1	  
33.6	   29.7	   27.5	  
33.1	   29.9	   26.3	  
35.86	   29.6	   28.2	  
	   	  
	  
Ct	  values	  for	  GAPDH	  
mRNA	  expression	  	   	   	  
FFPE	   HOPE	   Native	  
29.4	   25.5	   25.1	  
35.8	   29.7	   27.4	  
37.7	   27.9	   25.6	  
31.7	   28	   27.3	  
36.2	   27.9	   25.7	  
35.9	   27.8	   27.1	  
	   	   	  
	  
Ct	  values	  for	  β-­‐actin	  
mRNA	  expression	  	   	   	  
FFPE	   HOPE	   Native	  
36.9	   28.2	   26.7	  
38.7	   25.6	   24.1	  
31.8	   31.1	   25.8	  
34.2	   26	   25.5	  
33.2	   29.3	   28.1	  
38.12	   25.7	   24.8	  
 
Table 1: Mean cycle threshold values for the housekeeping genes TBP, GAPDH and ß-actin from 
the corresponding FFPE, HOPE, and fresh-frozen samples from three independent experiments 
(Braun and Menon et al., 2011). (88) 
 
D. Protein Analysis 
To assess for protein quantity and quality, proteins were extracted from FFPE, HOPE 
fixed and fresh frozen specimen and Western blots were then performed. For the 
FFPE and HOPE fixed samples, 3-8x10 µm sections were used and for fresh frozen 
samples 10-15x20 µm sections were transferred to a reaction tube for protein 
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extraction. 18 µg of protein was loaded into the gel for each sample. PSA and 
GOLPH2 were estimated, as both proteins are abundantly found in PCa (89). Western 
blots were performed using antibodies against PSA (Figure 14 A) and GOLPH2 
(Figure 14 B). Bands were observed at approximately 45-50 kDa and 34 kDa. The 
bands obtained for the HOPE fixed tissues were comparable to the intensity of the 
bands obtained from the fresh frozen tissue samples (Figure 14).  
 
Figure 14:  Western Blot analysis of HOPE, FFPE, and fresh-frozen samples 
(A) PSA (34 kDa) antibody and ß-actin (42 kDa) antibody as a control 
(B) GOLPH2 (45-50 kDa) antibody, and ß-actin (42 kDa) antibody as a control (Braun and Menon et 
al., 2011). (88) 
 
Furthermore, the signal intensities of the Western blots were quantified using the 
Scion Image software (Scion Corp., MD, USA). Upon normalization of the PSA and 
GOLPH2 antibodies’ signal intensities with that of β-actin, the analysis revealed that 
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all three fixation protocols had comparable signal intensities (Figure 15 A and B). 
Also, the protein yield from each fixation protocol was determined using the 
AxioVision Rel 4.8 (Carl Zeiss Imaging Solutions GmbH, Göttingen, Germany) by 
measuring the area of the section used for protein extraction. The protein yields for 
FFPE, HOPE and fresh frozen samples were also comparable and in some cases the 
HOPE and FFPE fixed specimen yielded higher proteins than the fresh frozen samples 
(Figure 15 C).  
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Figure 15:  Quantification of the Western blot. 
Western Blot for the (A) PSA antibody and (B) GOLPH2 antibody. (C) Measurement of protein yield 
for HOPE, FFPE and fresh frozen specimen (Braun and Menon et al., 2011). (88) 
 
The results of Objective I have been published in BMC Cancer titled, ‘The HOPE 
fixation technique- a promising alternative to common prostate cancer biobanking 
approaches.’ (Braun and Menon et al., 2011) (88). 
(A)
(B)
(C)
57
	  	  	  
7.2 Objective II: Determining the sequencing efficiency of FFPE tissue, in 
comparison to fresh-frozen tissue, both obtained from the same patient, using the 
SOLiD4 sequencing platform. 
Fresh frozen tissue of CRPC is very rare. This is due to the fact that patients suffering 
from the advanced form of PCa initially develop bone metastasis. If there are other 
treatment options available, patients are reluctant to undergo tissue biopsies (90). 
Furthermore, the limited available CRPC material is present in a FFPE fixed form and 
not as HOPE fixed material. The previous study analysed the efficiency of FFPE 
tissue to study DNA, RNA and protein. Based on the previous results, the second aim 
of the study was to examine the usability of FFPE tissue for sequencing. This was 
performed by obtaining a fresh frozen prostatectomy sample from a patient and 
dividing fresh it into two, and subjecting one half to FFPE fixation and fresh freezing 
the second half. Both halves were exome sequenced and data analysis was performed 
to determine the overlap between both. For normalization purposes, normal prostatic 
tissue from the same patient was used.   
A. Bioinformatic Analysis 
All three samples (FFPE non-tumor, FFPE tumor, and fresh frozen PCa tissues) were 
sequenced and the sequencing output from the SOLiD4 sequences results in many 
fragments that are 50 bp in length. The principle behind using 50 bp length fragments 
for sequencing is beneficial when using FFPE tissue as the tissue is degraded, 
damaged or in small quantities due to the formalin fixation protocol. These 50 bp 
fragments are randomly arranged and need to be aligned to the human reference 
genome. Previous groups have sequenced the human genome, which is approximately 
3 Gb (giga bases) in size. This reference genome is referred to as hg19. The 50 bp 
sequenced data was aligned with the human reference genome, hg19, in order to 
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identify single nucleotide variations (SNVs), insertions, deletions and amplifications 
within the patient sample. This alignment was performed using a software tool called 
BLAST-like fast accurate search tool (BFAST), which aligns the sequencing output 
character by character to the reference genome.  
A SNV can be denoted as a single nucleotide variation that occurs in the DNA of a 
genome in comparison to the genome of the biological species.  Similarly, an 
insertion/deletion (Indel) refers to the incorporation/removal of a few base pairs in the 
DNA with reference to the DNA of the biological species (Figure 16).  A mutation 
was denoted as a SNV/Indel where it was read more than 25 times in the sequence 
during the alignment step. The aligned sequence was given a scored called a PHRED 
score. The PHRED score is used to determine the quality and accuracy of the called 
base . The score is determined by evaluating the peak resolution and peak shape of the 
corresponding base. A score is then assigned by comparing the preexisting PHRED 
score tables for the correct base call (91, 92). 
Figure 16:  Data analysis pipeline identifying SNVs and Indels from a sequenced CRPC tumor 
sample. 
Generation of 50bp sequenced reads
Fragments aligned to the human reference genome (hg19)
Identi!cation of 
Single Nucleotide Polymorphism (SNP) Insertions/ Deletions (Indels)
ATGCGGCGATTGCCATGGGT
ATGCGGCGCTTGCCATGGGT
hg19
tumor sample
hg19
tumor sample
hg19
tumor sample
ATGCGGCGATTGCCATGGGT
ATGCGGCGA - - - CCATGGGT
Deletion
ATGCGGCGA - - TTGCCATGGGT
ATGCGGCGACATTGCCATGGGT Insertion
or
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Similarly a copy number variation (CNV) analysis was performed. A CNV refers to an 
abnormal number of copies of a DNA sequence in a cell. As all sequenced samples were 
human cancer tissues, a diploid copy number was expected. When the CNV analysis yielded 
more than two copies of a DNA sequence, it was referred to as amplification.  Similarly, a 
CNV analysis yielding less than two copies of a DNA sequences was referred to as a deletion. 
Normalization was performed using the non-tumor DNA from the same patient.  
Exome Sequencing of FFPE and Fresh Frozen PCa Tissue 
All three sequenced samples (FFPE non-tumor, FFPE tumor, and fresh frozen PCa 
tissues) yielded approximately 99 to 113 million reads. Uniquely mapped reads, or 
reads that uniquely aligned to the reference human genome (hg19), were 43.9 million 
for FFPE normal PCa, 42.5 million for FFPE tumor tissue and 51.0 million reads for 
the fresh frozen tumor tissue. From the unique reads, the percentage of reads that 
aligned were 81.9% for FFPE normal, 78.47% for FFPE tumor and 84.44% for fresh 
frozen tumor tissue. With reference to all the on-target reads, the percentage of 
targeted exons for each sample was 98.19% for FFPE normal prostatic, 98.32% for 
FFPE tumor and 98.52% for fresh frozen tumor (Table 2). 
Parameters	  
FFPE	  Normal	  prostatic	  
tissue	  
FFPE	  
Tumor	  
Fresh-­‐frozen	  
Tumor	  
Reads	   100,675,212	   99,910,447	   113,195,686	  
Rejected	  reads	   9,011,246	   10,280,465	   7,809,343	  
Valid	  reads	   91,663,966	   89,629,982	   105,386,343	  
Non-­‐uniquely	  mapped	  reads	   47,691,531	   47,113,995	   54,345,991	  
Uniquely	  placed	  reads	   43,972,435	   42,515,987	   51,040,352	  
On	  target	  reads	  (within	  +-­‐
150bp)	   36,016,954	   33,363,890	   42,077,913	  
On	  target	  reads	  in	  %	   81.91%	   78.47%	   82.44%	  
All	  Intervals/Exons	   165,481	   165,481	   165,481	  
Targeted	  exons	   162,490	   162,699	   163,027	  
Targeted	  exons	  in	  %	   98.19%	   98.32%	   98.52%	  
Non-­‐	  targeted	  exons	   2,991	   2,782	   2454	  
Total	  number	  of	  SNVs	   11,300	   8843	   12,183	  
Table 2: Comparison of exome sequence read data between FFPE normal prostatic, FFPE tumor 
and fresh-frozen tumor tissues  (Menon et al., 2012). (93) 
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B. Single Nucleotide Variation (SNV) Analysis 
SNVs were analyzed to draw a parallel between the sequenced FFPE tumor and fresh 
frozen PCa tissue. Of interest were the SNVs that were specific to the tumor tissues. 
A total of 11300 SNVs were identified for FFPE normal prostatic tissue, 8843 SNVs 
for FFPE tumor and 12184 SNVs for fresh frozen tumor tissue (Figure 17). The 
overlap of SNVs between the FFPE tumor and the fresh frozen tumor were 5873. 
66.4% of the SNVs identified in the FFPE tumor sample were common to the fresh 
frozen tumor sample (Figure 17 A). The tumor specific SNVs were identified after 
normalization with normal prostatic tissue.  There were a total of 2884 SNVs 
identified from the DNA obtained from FFPE tissue and 4837 SNVs identified for 
DNA obtained from fresh frozen tissue. There was a 41.9% overlap between the 
FFPE tumor and FFPE normal prostatic tissue (Figure 17 B). Similarly, there was a 
45.4% overlap between the fresh frozen tumor and FFPE normal prostatic tissue 
(Figure 17 C). A 66% between the DNA obtained from the FFPE tumor and the fresh 
frozen tumor suggests that FFPE tissue, could be a good alternative to fresh frozen 
tissue for sequencing.  
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Figure 17:  Venn diagrams representing SNV profiles  
(A) FFPE tumor vs. fresh frozen tumor tissue, (B) Fresh-frozen tumor vs. FFPE Normal prostatic tissue 
and (C) FFPE tumor vs. FFPE Normal prostatic tissue samples (Menon et al., 2012). (93) 
 
C. Copy Number Variation (CNV) 
A CNV analysis was performed between the FFPE tumor sample and the fresh frozen 
tumor sample. All samples were obtained from the same patient. In order to study the 
CNV, normalization was performed using normal prostatic tissue from the same 
patient. The CNV analysis was then plotted. Similarity was observed between the 
FFPE tumor and fresh frozen tumor tissue. For each chromosome, the ratio between 
normal and tumor tissue was calculated. Furthermore, the log2 was applied to the 
63112970 5873
537159592884
398373474837
(45.4%)
(33.6%) (66.4%)
(41.9%)
FFPE Tumor Fresh Frozen Tumor
Fresh Frozen Tumor FFPE Normal Prostatic Tissue
FFPE Tumor FFPE Normal Prostatic Tissue
(A)
(B)
(C)
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ratios. The genomic position is represented on the x-axis. The log2 ratios of the 
fragments are represented on the y-axis and the average is depicted by the red line. 
Chromosomes 17, 21 and 22 showed the best overlap for CNV analysis between both 
tissue types (Figure 18). These results show that there was an overlap between the 
copy number variation between the DNA obtained from the FFPE tumor and fresh 
frozen tumor tissues for a few chromosomes. The limitation in this study was the low 
sequencing coverage of the FFPE fixed tissues, therefore, a higher sequencing 
coverage would have generated an even more distinct overlap. 
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Figure 18: Representative copy number variation analysis (Chr. 17, 21 and 22) of exome 
sequenced fresh frozen tumor and FFPE tumor after normalization with FFPE normal prostatic 
tissue (Menon et al., 2011). (93) 
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The bioinformatic analysis was carried out by Mario Deng, the bioinformatician in the 
lab.  
The results of Objective II have been published in International Journal of Molecular 
Sciences titled, ‘Exome enrichment and SOLiD sequencing of formalin fixed paraffin 
embedded (FFPE) prostate cancer tissue’ (Menon et al., 2012) (93).  
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7.3 Objective III: Identification of novel therapeutic targets for castration 
resistant prostate cancer by whole exome sequencing, and functional validation 
of the identified targets. 
Having confirmed the usability of FFPE tissue for whole exome sequencing 
(Objective II), the central aim of the project was to perform exome sequencing on 
CRPC patient samples to detect mutations/deletions/insertions which encode for 
genes that could be potential therapeutic targets. The exome sequencing cohort 
consisted of five CRPC patient samples. The organs of metastasis included lung, 
rectum, stomach and kidney. For each patient sample, there was corresponding non-
tumor tissue for normalization purposes to identify somatic copy number alterations 
and SNVs specific to the tumor. The organ sites for the non-tumor tissue included 
lung, kidney and liver. All samples were obtained from the University Hospital of 
Tuebingen, Germany with the approval of the Institutional Review Board 
(395/2008BO1). The five sequenced patients had undergone hormonal therapy for 
CRPC and were negative for the TMPRSS2-ERG gene fusion.  
 
A. Exome Sequencing Using the SOLiD4 platform 
The average coverage for the five CRPC and their corresponding non-tumor samples 
that were exome sequenced was >50x and the average read length was 50bp. The five 
sequenced samples were aligned to the reference genome (hg19) and 
bioinformatically analyzed using the bioinformatic pipeline mentioned in Objective II. 
All the tumor CRPC samples were normalized using corresponding non tumor tissue 
from the same patients to identify amplifications and deletions. The aligned files were 
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viewed using the Integrative Genome Viewer 2.2 (Massachusetts, USA). Regions of 
amplification in three or more samples included 1q23.2-q32.2, 8q12.1-q24.21, 
16p13.3-11.2, 17q24.2-25.3 and Xp22.2-p22.11. Regions of deletion included 
chromosome 8p22-p22.2, 11q22.3-23.3, 16q12.2-24.2, 17p13.2-12, 18q12.2-23, 
19q13.11-13.3 and 22q12.2-13.32 (Figure 19). Furthermore, to validate the 
sequenced data, well-known amplifications (cMYC, AR) and deletions (PTEN, 
NKX3.1) in PCa were also identified in the in the DNA of the CRPC patients (Figure 
19). 
 
 
Figure 19: Somatic copy number alternations and validation of the five sequenced CRPC 
samples.  
Regions of amplification were depicted in red, regions of deletion were depicted in blue and copy 
number neutral regions were depicted in white. Exemplary genes (cMYC, NKX3.1, PTEN, AR) 
previously known to be amplified/deleted in CRPC were also identified in our discovery cohort. 
(Menon et al., Manuscript in preparation).  
 
B. Cross Validation of Somatic Copy Number Gains and Losses by Data Mining  
We identified certain regions of amplification and deletions in our CRPC cohort. The 
amplifications that were observed included the AR co-activator gene NCOA2 (SRC-2) 
(nuclear receptor coactivator 2), a cluster of amplifications on chromosome 8 
comprising of TERF1 (telomeric repeat binding factor), RPL7 (ribosomal protein L7), 
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STAU2 (staufen, RNA binding protein, homolog2), UBE2W (ubiquitin-conjugating 
enzyme E2W), COX6C (cytochrome c oxidase subunit VIc), and GRHL2 
(grainyhead-like 2). Furthermore, there were deletions of the tumor suppressor genes 
LATS2 (large tumor suppressor, homolog2), PLAG1 (pleiomorphic adenoma gene 1), 
RB1 (retinoblastoma 1), HSD17B2 (hydroxysteroid (17-beta) dehydrogenase 2), and 
HSDL1 (hydroxysteroid dehydrogenase like 1), BIN3 (bridging integrator 3), 
RHOBTB2 (Rho-related BTB domain containing 2), CHMP7 (charged multivesicular 
body protein 7), LOXL2 (lysyl oxidase-like 2), and FUT10 (fucosyltransferase 10). 
Our data regarding the amplifications and deletions from the exome sequenced CRPC 
cases is consistent with the recent finding reported in sequencing performed on fresh 
frozen CRPC samples (82). Moreover, we found an amplification of PIK3CA 
(phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha), HOXA3 
(homeobox A3), AR, and deletions of CHD1 (chromodomain helicase DNA binding 
protein 1), NT5E (5'-nucleotidase), PTEN, RB1 and TP53, also described in another 
recent sequencing study on fresh frozen CRPC samples (85).  
 
C. Validation of Somatic Copy Number Gains and Losses by FISH and SPOP 
Mutational Analysis 
The commonly found alterations found in all PCa patients include the NKX3.1 
deletion, AR amplification and cMYC amplification. On the other hand, PTEN 
deletion was observed only in one of the patient samples. Furthermore, FISH assays 
were performed on the above mentioned commonly found alterations in PCa (ERG, 
PTEN, cMYC, AR, NKX3.1) on a PCa progression cohort to identify the frequency of 
a PCa stage specific deletion/amplification. This cohort consisted of clinically 
localized PCa, LN metastasized PCa and CRPC. BAC clones were used for the FISH 
68
	  	  	  
assays and were identified using the Ensembl genome browser online tool. A split 
signal (Figure 4) was used to identify the TMPRSS2-ERG gene fusion by FISH. 
Similarly, for the potentially amplified or deleted genes, a reference probe spanning 
the centromere of the corresponding probe was used. The target probes were labeled 
with biotin to produce a red signal.  
NKX3.1 was deleted in 32% of the localized PCa, 88% in LN metastasized PCa and 
91% in CRPC. Similarly, PTEN deletion was observed in 1% of the localized PCa, 
26% of the LN metastasis samples and in 23% of the CRPC. The frequency of 
patients harboring the deletion of these tumor suppressor genes was lowest in 
localized PCa and highest in CRPC. Well know oncogenes, such as cMYC, were 
amplified in 1% of localized PCa, 8% of LN metastasized samples and 16% of the 
CRPC.  Similarly, AR, known to be amplified in advanced PCa, also exhibited the 
same trend (83). AR amplifications were only seen in the CRPC samples at a 
frequency of 40%. On the other hand, the frequency of the ERG rearrangement was 
highest in localized PCa at a frequency of 49%, 46% in lymph node metastasized 
cases and lowest in CRPC with a frequency of 28% (Figure 20) (94). These results 
indicate that the data obtained from the sequencing performed on the CRPC patients 
showed representative genes expected to be amplified or deleted based on the stage of 
disease. For example, the AR amplification frequency was highest in CRPC of the 
progression cohort, similarly all five of the sequenced patients also harbored the 
amplification. Similarly, the tumor suppressor gene NKX3.1, was deleted at a high 
frequency in CRPC of the progression cohort, was also deleted in all the five CRPC 
sequenced patients possibly due to the advanced stage of disease. 
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Figure 20:  FISH validation of genes known to be amplified/deleted/rearranged in PCa.  
The frequency of genetic alterations was determined with regards to the tumor stage from primary PCa 
to CRPC (Menon et al., Manuscript in preparation).  
 
Furthermore, all five sequenced CRPC patients were negative for the TMPRSS2-ERG 
gene fusion. A recent study reported that patients negative for the gene fusion were 
positive for mutations in the SPOP gene, thereby creating a new molecular subtype 
for PCa (86). The five CRPC patient DNA was also subjected to resequencing for 
SPOP mutations, but no mutations were identified. SPOP mutations are seen in up to 
6-15% of all prostate tumors (86). Our sequencing cohort was very small and 
therefore may be the reason due to which the mutation was not detected.  
 
D. Identification of Novel Therapeutic Drug Targets for CRPC  
After having validated the CRPC exome sequencing data by identifying 
amplified/deleted/mutated genes through FISH and resequencing, the next aim was to 
identify novel alterations in genes that could serve as potential therapeutic targets in 
CRPC.  
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The sequencing coverage of the five CRPC patients was an average of 50x. This 
coverage was too low to distinguish between actual SNVs and false positives induced 
due to FFPE fixation. However, the mutational analysis did identify a few mutations 
commonly found in PCa, which included amongst others: rs198977 (KLK2), 
rs2233324 (NDRG1), rs422471 (TMPRSS2), rs1337076 (AR). The rs numbers refer to 
the reference number of the SNV that has been previously recorded in the mutation 
database and has been detected in PCa.  
Due to the low coverage, it was difficult to identify SNVs that could serve as 
therapeutic targets. Therefore, the data analysis was focused on the copy number 
variation analysis.  Focusing on the copy number variation analysis, amplified genes 
were identified that could serve as potential therapeutic target for CRPC.  
Regions of amplification and deletion were identified throughout the exome. A total 
of 928 genes were amplified and a total of 647 genes were deleted (Appendix I and 
II). 
Amongst all the regions of amplification, the 8q region has been previously described 
in prostate cancer and it also harbors the amplification of the oncogene cMYC (95). In 
the sequenced data, this 8q amplicon was present in all five sequenced samples. 
Therefore, this 8q region was studied in further detail to identify genes having 
oncogenic potential and therapeutic significance in CRPC. In the 8q region, firstly, 
genes known to play a role in cancer were identified. Secondly, the search was further 
narrowed by identifying genes with commercially available inhibitors. Lastly, from 
this list, the focus was centered on genes studied to a limit extent in PCa. Amongst all 
the genes in the 8q amplicon, two genes that were amplified at a higher frequency 
than cMYC were YWHAZ and PTK2. YWHAZ is present on 8q22.3 and PTK2 is 
present on 8q24.3. These two genes were amplified in the CRPC sequenced cases.  
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These two genes were further validated on the PCa progression cohort and the 
somatic copy number variation was analyzed by FISH (Figure 21 and 22). The 
amplification status of the two genes in the five sequenced patient samples was also 
further confirmed by FISH. A case was amplified when 80-100% of the cells in the 
case harbored the amplification.  
Regarding YWHAZ, 3.7% of the cases were 1mplified in localized PCa, 25.4% in LN 
metastasis and 48.4% in CRPC (Figure 21 B). The frequency between all three 
subsets was significantly different.  
 
 
 
Figure 21:  YWHAZ amplification in the PCa progression cohort.  
A. Schematic representation of the BAC clones spanning the YWHAZ gene at chr.8q22.3. 
B. Frequency of YWHAZ amplification determined in the PCa progression cohort using FISH.  
(* Indicates a significant effect (p<0.05) 
C. Representative nuclei of the patient samples analyzed by FISH. The amplification can be observed 
as copy number>2 red target signals in comparison to green reference signals. Non-amplified nuclei 
(N) are represented in a diploid state with two red and two green signals.  
 (Menon et al., Manuscript in preparation).  
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For PTK2, we found 1.8% of the cases to be amplified in localized PCa and 32.8% in 
LN metastasis and 35.5% in CRPC. The amplification frequency between the primary 
PCa and LN metastasized PCa, and CRPC was highly significant (Figure 22 B).  
 
 
 
 
Figure 22: PTK2 amplification in the PCa progression cohort.  
A. Schematic representation of the BAC clones spanning the PTK2 gene at chr.8q24.3. 
B. Frequency of PTK2 amplification determined in the PCa progression cohort using FISH.        (* 
Indicates a significant effect (p<0.05) 
C. Representative nuclei of the patient samples analyzed by FISH. The amplification can be observed 
as copy number >2 red target signals in comparison to green reference signals. Non-amplified nuclei 
(N) are represented in a diploid state with two red and two green signals.  
 (Menon et al., Manuscript in preparation).  
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Furthermore, the amplification status of the genes were correlated with their protein 
expression in the PCa progression cohort. The protein expression was digitally 
quantified using an image analysis software (Tissue Studio v.2.1, Definiens AG, 
Munich, Germany) to assign a number to each case depending on the average staining 
intensities. The IHC stained slides were scanned and the tumor cells were circled in 
each case. The software then detected the staining intensity for each patient sample 
and assigned a number based on the intensity. For both YWHAZ and PTK2, the 
amplified cases had a significantly higher protein expression in comparison to the 
non-amplified cases (Figure 23 B and 24 B). For PTK2, the phosphorylated antibody 
(pPTK2) was used to determine the protein expression. The phosphorylated form is 
the active form of PTK2.  
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Figure 23: YWHAZ protein expression in the PCa Progression cohort assessed by 
immunohistochemistry. (* Indicates a significant effect (p<0.05)) 
A. YWHAZ expression in representative prostate cancer tissue samples indicating a strong cytoplasmic 
and nuclear expression. The strong positively stained case is assigned a number 1.0 based on its 
staining intensity whereas the negative case is assigned a 0.29 based on a weak staining.  
B. A graph showing the Definiens assigned mean YWHAZ protein expression values (Y axis) in 
YWHAZ amplified and non-amplified PCa cases (X axis). The protein expression is significantly higher 
in the YWHAZ amplified samples.  
 (Menon et al. Manuscript in preparation).  
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Figure 24: pPTK2 protein expression in the PCa Progression cohort assessed by 
immunohistochemistry. (* Indicates a significant effect (p<0.05)) 
A. pPTK2 expression in representative prostate cancer tissue samples indicating a strong cytoplasmic 
expression. The strong positively stained case is assigned a number 0.8 based on its staining intensity 
whereas the negative case is assigned a 0.0. 
B. A graph showing the Definiens assigned mean pPTK2 protein expression values (Y axis) in PTK2 
amplified and non-amplified PCa cases (X axis). The protein expression is significantly higher in the 
PTK2 amplified samples.  
 (Menon et al., Manuscript in preparation).  
 
 
These results indicate that the frequency of both PTK2 and YWHAZ amplifications is 
highest in CRPC patients. Furthermore, there is a positive correlation between 
genomic amplification and protein expression.   
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E. The Amplification and Expression of YWHAZ and PTK2 in PC-3 cells 
In order to determine the functional role of YWHAZ and PTK2 amplifications in PCa, 
we identified a cell line harboring both gene amplifications. The PC-3 cell line is an 
androgen independent cell line derived from bone metastasis. These cells revealed a 
high level amplification, for both, YWHAZ and PTK2 when assessed by FISH (Figure 
25 A and C). Western Blots were performed to detect protein expression within the 
cell line. (Figure 25 B and D).  
 
 
 
Figure 25: YWHAZ and PTK2 amplification and protein expression in the PC-3 cells 
A. YWHAZ amplification, determined by FISH, in the PC-3 cells in the interphase and the metaphase.  
B. YWHAZ protein expression determined by Western Blot in the same cell line. 
C. PTK2 amplification, determined by FISH, in the PC-3 cells the interphase and the metaphase.  
D. PTK2 protein expression by Western Blot in the same cell line  
 (Menon et al., Manuscript in preparation).  
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F. Effect of YWHAZ Knockdown on Proliferation and Migration/Invasion in the 
PC -3 cells 
To evaluate the role of YWHAZ in cancer progression, studies were performed to see 
what effect the YWHAZ knockdown would have on proliferation and 
migration/invasion. As shown above, YWHAZ is expressed in the PC-3 cell line. The 
endogenous protein expression was reduced by performing a knockdown using 
siRNA specific to the gene. The siRNA used for the knockdown included duplexes 
specific for YWHAZ and a four siRNA pooled oligonucleotide sequence targeting 
YWHAZ. In parallel, a non-targeting scrambled siRNA was used as a control. Upon 
adding siRNAs the YWHAZ knockdown was evident after 72 hrs of treatment 
(Figure 26).  After the knockdown, its effect on migration and proliferation was 
measured.   
 
 
 
Figure 26: Representative YWHAZ expression by Western Blot 72 hrs after knockdown in the 
PC-3 cells.  
YWHAZ protein expression was significantly reduced after 72 hrs of treatment with siRNA.  
 (Menon et al. Manuscript in preparation).  
 
The effect of the knockdown on proliferation was assessed after 24, 48 and 72 hrs by 
performing an MTT assay. At the 72 hr time point, the proliferation of the cells 
YWHAZ
PC-­3  cells
un
tre
ate
d
72  hrs
siR
NA
  ta
rge
t
siR
NA
  sc
ram
ble
d
ȕ-­ACTIN
78
	  	  	  
treated with targeting siRNA, was significantly lower than the control group (Figure 
27). 
  
 
 
Figure 27: Measurement of cell proliferation using the MTT assay on the YHWAZ knocked down 
PC-3 cells after 24 hrs, 48 hrs and 72 hrs.  
Percentage of viable cells was calculated by using the mean of three independent experiments. There 
was a significant decrease in proliferation between the control group and the knocked down cells (* 
Indicates a significant effect (p<0.05)) 
(Menon et al., Manuscript in preparation).  
 
To test for the effect of the knockdown on migration, a Boyden Chamber 
migration/invasion chamber was performed. The targeted siRNA treated cells had 
significantly lower migration ability compared to the control group. There was a 55% 
decrease in migration in comparison to the control-scrambled siRNA. The difference 
between the control group, treated with scrambled siRNA, and cells with YWHAZ 
knocked down was highly significant (Figure 28). 
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Figure 28: Migration/invasion assay for the PC-3 cells harboring the YWHAZ knockdown.  
Percentage of invading cells was calculated by using the mean of three independent experiments There 
was a 55% decrease in migration in the knocked down cells when compared to the control          
(* Indicates a significant effect (p<0.05)) (Menon et al., Manuscript in preparation).  
 
These results indicate that the YWHAZ knockdown did affect cell proliferation and 
migration. Therefore, blocking YWHAZ could potentially reduce PCa progression.  
 
G. Effect of the pharmacological PTK2 inhibitor, TAE226, on PC-3 cells 
Similarly, the effect of pPTK2 suppression on the PC-3 cell line was determined by 
treating the cell line with the commercially available pharmacological TAE226 
inhibitor. The cell line was treated with a gradient of the TAE226 inhibitor (0-10 µM). 
Similarly, the effect of the inhibitor was tested on cell proliferation and migration. A 
Western Blot was performed to analyze the reduction in protein expression at each 
time point (Figure 29). DMSO treated cells were used as a control. 
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Figure 29: Representative phospho PTK2 expression by Western Blot after treatment with the 10 
µM TAE226 pharmacological inhibitor after 24, 48 and 72 hrs.  
There was a time dependent gradual decrease in protein expression after treatment with the inhibitor 
(Menon et al. Manuscript in preparation).  
 
There was a significant reduction in pPTK2 expression at a concentration of 10 µM of 
the inhibitor.  After 72 hrs of exposure to the inhibitor, a significant decrease in cell 
proliferation was observed at the same concentration (Figure 30).   
 
Figure 30: Measurement of cell proliferation using the MTT assay on the PC-3 cells treated with 
10 µM TAE226 pharmacological inhibitor after 24, 48 and 72 hrs.  
Percentage of viable cells was calculated by using the mean of three independent experiments The least 
number of viable cells were observed after 72 hrs of treatment with the inhibitor 
(* Indicates a significant effect p<0.05) (Menon et al., Manuscript in preparation).  
 
The data suggests that the inhibitor had a significant effect on cell proliferation. As a 
control, the cells were treated with a 10 µM concentration of DMSO. 
Next a cell cycle analysis was performed to see the stage at which the cells are 
arrested when exposed to the inhibitor. The cells were subjected to a PI staining 
assessed by flow cytometry. PI intercalates in the deep groove of double stranded 
DNA.  
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As shown in Figure 31, after 24 hours of treatment with the inhibitor, the majority of 
the cells were arrested at the G1 phase. After 48 hours of treatment with the inhibitor, 
a majority of the cells were arrested in the G2 phase. Eventually, 72 hrs of treatment 
with the inhibitor majority of cells were arrested at the G1 phase, followed by the G2 
phase. There was a decrease in the number of cells in the S-phase after all three time 
points (Figure 31). As a control, the cells were treated with a 10 µM concentration of 
DMSO.
 
 
Figure 31: PI staining cell cycle arrest assay for PC-3 cells treated with pharmacological TAE226 
inhibitor.  
A. Representative cell cycle analysis of PC-3 cells treated with DMSO and pharmacological TAE226 
inhibitor. 
B. Percentage of viable cells was calculated by using the mean of three independent experiments. At a 
10 µM concentration, the cells are arrested at the G1 and G 2/M phase. There was a decrease in the 
number of cells in the S-phase. (* Indicates a significant effect p<0.05) (Menon et al., Manuscript in 
preparation).  
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Next, the effect of the inhibitor in inducing apoptosis was tested. This was done by 
performing a Hoechst 33342/Yo Pro-1 apoptosis assay with the inhibitor at a 10 µM 
concentration. The inhibitor is dissolved in DMSO. Therefore, as a control, the cells 
were treated with a 10 µM concentration of DMSO to test for apoptosis. Hoechst 
33342 stains the condensed chromatin of apoptotic cells and dimly the chromatin of 
live cells. Yo Pro-1 enters the apoptotic cells. The FACS staining showed cells in four 
different quadrants. Apoptotic cells are Yo Pro-1+ and Hoechst 33342- and +, while 
viable cells are Yo Pro-1 and Hoechst 33342-. shown in the left upper quadrant while 
viable cells are in the lower left quadrant. Doxorubicin was used as a positive control 
and at a concentration of 10 µM, it induced apoptosis in 99% of the cells. On the other 
hand, only 4% of the untreated cells underwent apoptosis. After 72 hrs of treatment 
with the inhibitor, a negligible amount of cells were apoptotic (12%). Therefore, the 
results of this assay showed that the inhibitor at high concentrations of 10 µM did not 
induce apoptosis in the cells (Figure 32).  
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Figure 32: Representative FACS analysis data to determine apoptosis in the TAE226 treated  
PC-3 cells by staining with YO-PRO-1 (X axis) and Hoechst 33342 (Y axis).  
The positive control, Doxorubicin, at a 10 µM concentration induced apoptosis in the cells. Negligible 
amount of cells were apoptotic at the highest inhibitor concentration of 10 µM. In this figure the colors 
designate the density of the cell population where blue is the least dense and red is the most dense  
(Menon et al. Manuscript in preparation).  
 
Furthermore, the PTK2 inhibited cells were subjected to migration/invasion in vitro. 
The pharmacological TAE226 inhibitor treated cells had a significant decrease in 
migration compared to the untreated PC-3 cells. The difference in invasion capacity 
of the control group versus the PTK2 inhibited cells was highly significant (Figure 
33).  
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Figure 33: Migration/invasion assay for PC-3 cells treated with the pharmacological inhibitor at 
a concentration of 10 µM. 
Percentage of invading cells was calculated by using the mean of three independent experiments. There 
was a 40% decrease in migration compared to the control group. 
(Menon et al.,Manuscript in preparation).  
 
These results indicate that the PTK2 inhibited PC-3 cell line did show a significant 
decrease in proliferation and migration. Furthermore, upon treatment with the 
pharmacological TAE226 inhibitor, the cells were arrested at the G1 and G2 phase. 
Therefore, the PTK2 gene  could potentially serve as a therapeutic target for CRPC 
patients. 
  
The results of Objective III are presented in a manuscript which is under preparation., 
‘Somatic copy number alterations by whole exome sequencing implicates YWHAZ 
and PTK2 in castration resistant prostate cancer’ (Menon et al., 2013 Manuscript in 
preparation).  
The bioinformatic analysis was carried out by Mario Deng, the bioinformatician in the 
lab.  
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8. Discussion 
 
PCa translational research requires the availability of well-annotated human prostate 
tissue samples (96-99). However, for clinical practices, hospitals require all prostatic 
tissue to be available for diagnostic purposes. Due to this requirement, the availability 
of fresh frozen tissue for research purposes in very limited. It has been previously 
shown that FFPE tissue is easy to handle and store (100). Most of the material 
available in the pathology archives is present in FFPE form. Therefore, there is a need 
to assess the quality of FFPE fixed tissue for research purposes, in particular next 
generation sequencing.   
8.1 Validation of FFPE and HOPE fixed tissue for DNA, RNA and protein 
analysis 
A comparative study was performed using HOPE fixed, FFPE fixed and fresh frozen 
tissue to analyze DNA, RNA and protein integrity. HOPE fixed specimen yielded far 
better results than the FFPE fixed specimen (Figure 11,12,13,14). HOPE fixation did 
not present nucleic acid degradation and methylene cross-linking, they displayed 
superior morphology and also required no antigen retrieval for IHC analysis. For the 
FISH analysis, the HOPE samples required enzymatic pretreatment for better signals. 
DNA extracted from all three fixation methods yielded good results, appropriate for 
molecular downstream applications (Figure 12). Unfortunately, due to fixation, RNA 
obtained from FFPE specimens were fragmented (Figure 13). On the other hand, 
FFPE samples could be successfully used for amplification of shorter fragments of up 
to 400bp in length.  
Our study was the first to extensively analyse the efficiency of the HOPE fixation 
protocol for research purposes. In a pathology setting, the most commonly used 
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fixation protocol is FFPE as these samples are cheap and easy to handle. DNA 
extraction from FFPE tissues have previously been studied by various groups (101-
103). Our study yielded better results for DNA extracted from the HOPE specimen in 
comparison to the FFPE specimen. Similar to our results, a study performed by Gupta 
et al., noticed a 100 fold enhanced sensitivity for the HOPE fixed material, in 
comparison to the formalin fixed material (104). Furthermore, another study by 
Wiedorn et al., supports our study. They claim that high molecular weight nucleic 
acids are preserved when specimen are HOPE fixed (105).   
 With regards to RNA extraction and integrity, a similar study conducted by Arzt et 
al., compared the RNA extraction protocols for HOPE and FFPE fixed specimen. 
They found that they had a higher yield of RNA in the FFPE extracted samples when 
compared to the HOPE samples (106). Also, they reported that the RNA integrity was 
the same for both fixative techniques. On the contrary, in our study, FFPE specimen 
fared better than the HOPE specimen. A reason for the difference in RNA based 
results may be due to the modifications introduced by the authors in the RNA 
extraction protocol. The authors used two different kits for RNA extraction, and an 
addition purification step (106). A major limitation in our study was the lack of 
Bioanalyzer data to determine RNA integrity. A Bioanalyzer analysis in addition to 
the qRT-PCR analysis would have strengthened our study. Furthermore an optimized 
RNA extraction protocol could also drastically increase the RNA yield from the fixed 
specimen.  
With regards to protein extraction, a study conducted by Uhlig et al., showed the 
efficiency of HOPE fixed specimen in western blot analysis (107). They compared 
specimen that were fixed 2-4 year ago, and noticed that in the HOPE fixed specimen, 
the antigens on the cell surfaces were intact. In our study, we studied prostate cancer 
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tissue that was HOPE, FFPE and cryofixed a few days prior to the experiments. 
Therefore, we did not take into consideration the prolonged effect of fixation on the 
specimen, which is a limitation of our study. The impact of the fixation on RNA , 
DNA and protein, over a prolonged period of time was not taken into consideration. 
Therefore, a study assessing this effect of fixation on DNA, RNA and protein would 
help in identifying the ideal fixation protocol for sequencing based studies.  
All in all, this was the first paper to compare HOPE, FFPE and fresh frozen tissue for 
RNA, DNA and protein analysis. 
 
8.2 Validation of exome sequencing efficiency of FFPE tissue  
The study of genomic and transcriptomic alterations in cancer has been made possible 
by the emergence of next generation sequencing technologies (108). These 
technologies have enabled the detection of mutations, substitutions, insertions, 
deletions, and copy number alterations. Fresh frozen tissue is the most commonly 
used tissue type for sequencing due to its high DNA and RNA integrity. Due to the 
scarcity of fresh frozen CRPC, a pilot study was conducting using FFPE tissue for 
sequencing. The abundant availability of FFPE tissue in the pathology archives would 
facilitate the use of FFPE material for sequencing would provide an in-depth analysis 
of the functional biology of cancer, cancer progression and drug therapy. 
Unfortunately, the use of FFPE material for RNA sequencing is limited. Due to the 
fixation and instability of RNA, it is very difficult to extract high integrity RNA. 
Therefore, transcriptome sequencing still remains a challenge as FFPE material is 
only suitable for DNA based sequencing protocols. 
To test for the exome sequencing efficiency of FFPE material, a pilot study was 
performed to compare the sequencing results obtained from both fresh frozen and 
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FFPE fixed PCa tissue from a single patient. The results of this study showed that 
66% of the SNVs detected in FFPE tissue were also seen in the fresh frozen tissue 
(Figure 17). These positive results lead to the next objective. A major limitation of 
our study was the low sequencing coverage. Several studies have shown that a high 
sequencing coverage of 100x or more drastically decreases the detection of false 
positives SNVs and is sufficient for a reliable CNV analysis (109, 110).  
 
8.3 Identification of genes, by whole exome sequencing, that could serve as 
druggable targets for CRPC 
With regards to PCa, in particular, treatment options for patients suffering from CRPC 
still remains a significant challenge. There is an urgent to identify therapeutic targets 
for CRPC using tools such as next generation sequencing techniques. The objective of 
this study was also to identify relevant genes that could serve as druggable targets for 
CRPC by performing exome sequencing on five CRPC/normal paired samples. Due to 
the scarcity of CRPC fresh frozen material, FFPE material was used for exome 
sequencing.  
Our exome sequencing data identified many areas of amplification and deletions in 
the CRPC samples (Figure 19). Recent sequencing studies on CRPC fresh frozen 
material identified several clusters of amplification on chromosome 8 and other 
chromosomes (82, 85). These clusters were also identified in our sequencing data. 
The genes that were amplified on chromosome 8 included TERF1, RPl7, STAU2, 
UBE2W, COX6C, and GRHL2.   
Among the amplicons in our exome sequenced data, the 8q region was amplified in 
all five sequenced patients. The 8q amplicon also harbors the proto-oncogene 
cMYC(111, 112). Two more genes residing on chromosome 8, namely YWHAZ and 
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PTK2, were also amplified in all five patients. Furthermore, the latter two genes were 
amplified at a much higher frequency than the well known proto-oncogene cMYC 
(95). Of note, the amplification frequency of YWHAZ was 3.7% in the localized PCa 
cases and 48.4% in CRPC patients. Similarly the amplification frequency of PTK2  
increased from 3.7% in localized PCa to 48.4% in CRPC. This shows that the 
amplification frequency for both genes was the highest in CRPC patients (Figure 21 
and 22).  
YWHAZ, a 14-3-3 family protein, is overexpressed and up-regulated in various 
cancers and is also a drug target in head and neck cancers and breast cancer (113-
115). This gene is involved in many cellular processes such as metabolism, protein 
trafficking, signal transduction, apoptosis and cell cycle regulation. In head and neck 
tumors, the amplification of the gene resulted in neoplastic transformation. 
Furthermore, the cells were resistant to apoptosis and had accelerated cell growth 
(116). In breast cancer, YWHAZ induced chemotherapy resistance, and played a vital 
role in the partial transformation of human mammary epithelial cells (HMECs) (117). 
There are commercially available inhibitors for the 14-3-3 family of proteins, namely 
Difopein and R18. Unfortunately, they do not target the YWHAZ but the whole family 
of genes. Therefore, to specifically target YWHAZ, siRNAs specific to the gene were 
used. These siRNAs were previously also used for the study of YWHAZ and its role in 
breast cancer (115). Results obtained by the studies performed on the head and neck 
cell lines and breast cancer cell lines showed that YWHAZ knockdown enhanced 
anchorage independent growth and made cells more sensitive to stress induced 
apoptosis (113, 116). In our functional studies, the knockdown resulted in decreased 
proliferation and migration (Figure 27 and 28). Based on the results of this study, 
there is a necessity to develop drugs specifically targeting YWHAZ. One limitation to 
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this experiment involves the off target effects of the siRNA. siRNAs are known to 
introduce off targets effects such as multiple site cleavage or a translational block due 
to imperfect match of the 3’ UTR (118). Creating a PC-3 cell line harboring a stable 
knockdown of the gene could eliminate these off-target effects. 
Furthermore, a recent publication elucidated the role of YWHAZ in prostate cancer 
LNCaP cells, which is an androgen responsive cell line (119). This group showed that 
upon treatment with DHT, LNCaP cells showed and increased expression of YWHAZ 
and also promoted proliferation and motility. Upon immunoprecipitation, it was 
shown that YWHAZ associated with the androgen receptor. The gene increased AR 
transcriptional activity by binding to the receptor in the nucleus. These studies support 
the role that YWHAZ has in patients harboring an AR amplification. It is known that 
10-30% of the CRPC patients harbor and AR amplification (120). Therefore, a 
cocktail of antiandrogen drugs in combination with drugs specifically targeting 
YWHAZ could cumulatively have an effect in halting PCa progression.  
YWHAZ has been described be involved in various cell processes but there is limited 
information on the biological function of the gene. YWHAZ has three sites that are 
phosphorylated by PBK/Akt phosphorylation. This induces the dimerization and 
activation of the gene (121). Furthermore, another interaction partner of YWHAZ is 
beta-catenin. The gene has been shown to activate beta-catenin through survival 
kinase Akt. And beta-catenin in turn activates the Wnt responsive genes in the Wnt 
signaling pathway. All these pathways play a role in furthering tumorigenesis (122). 
Also, YWHAZ studies have shown that knockdown results in decreased MAPK and 
AKT activity. In turn MAPK and AKT are associated with apoptotic molecules such 
as Bcl2 and Bax, which act complementary to each other (123). As YWHAZ is known 
to interact with various signaling pathways, it is important identify its biological and 
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functional role. To further understand the activation and pathways the gene interacts 
with, it would be interesting to perform a knockdown/overexpression of YWHAZ in a 
PCa cell line followed by an expression chip analysis. This would give an overview of 
the genes that are up or down regulated in the cell line harboring the overexpression 
or knockdown. Furthermore, the up or down regulated genes would also provide a 
brief overview regarding the signaling pathways involved. Another experiment that 
could be conducted is coimmunoprecipitation to assess for the binding partners of 
YWHAZ. As this gene has not been extensively studied in literature, much remains to 
be done to understand its biological relevance. 
Similarly, PTK2 is another gene, known to play a role in decreased cell adhesion and 
increased cell survival in ovarian, gastric and breast cancers (124-126). For PTK2, the 
phosphorylation of the amino acid Y397, induces the formation of the PTK2-Src 
complex and activates it (127-129). The Src family kinases play a major role in 
integrin signaling. Upon phosphorylation of the Y397 and formation f the PTK2-Src 
complex various signal transduction pathways are triggered (130). The PTK2-Src 
complex, in breast cancer, is involved in ERK activation through the ERK-MAPK 
pathway to maintain tumor growth and migration (126). Studies using the PTK2 
specific inhibitor have been shown to decrease migration, invasion and proliferation 
in cancers (127, 131, 132).  The pharmacological TAE226 inhibitor, a PTK2 specific 
inhibitor, reduces levels of phosphorylated PTK2 by inhibiting both the Y397 and 
Y861 phosphorylation (127, 133). In ovarian cancer, the inhibitor has shown to be 
effective in both chemotherapy sensitive and resistant ovarian cancer models (127). 
When our CRPC PC-3 cells were treated with inhibitor, they exhibited a significant 
decrease in both migration and proliferation (Figure 30 and 33). Furthermore, the 
flow cytometry analysis of the PI staining showed cells arrested in the G1 and G2/M 
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phases. Therefore, similar to YWHAZ, PTK2 could also serve as a potential 
therapeutic target for CRPC and the pharmacological TAE226 inhibitor could be 
provided to patients in combination with other cancer drugs to treat PCa.  
PTK2 is also known as focal adhesion kinase (FAK). It is a part of the non receptor 
tyrosine protein kinase and is required for many normal cellular functions such as cell 
proliferation, differentiation, migration, adhesion (134). PTK2 is up regulated in 
gliomas and breast cancers. The TAE226 inhibitor has been tested in gliomas and 
breast cancer. It inhibited the phosphorylation of Y397 and insulin like growth factor 
I. Furthermore, it also inhibited downstream targets genes such as Akt (135). As the 
inhibitor has provided successful results in glioma and breast cancer xenograft models 
(131), the next step would be to test the inhibitor on prostate xenograft models. This 
would essentially bring us closer to determining the role of PTK2 as a therapeutic 
target in CRPC.   
An extension to the YWHAZ experiments would involve using the DU-145 PCa cell 
line, not harboring the YWHAZ amplification, to stably overexpress the gene. The 
effect that the stable transfection has on migration and proliferation would be 
assessed. Furthermore, these cells could be introduced in mice to see whether it leads 
to an increase in tumor growth and cell migration. In parallel, the PC-3 cell line could 
be used to create a stable knockdown for YWHAZ, followed by assessing the 
migration and proliferation characteristics of the cells. Based on the results obtained, 
they could also be introduced into mice. The creation of stable cells lines would help 
in erasing the off target effects caused by siRNA.  
Similarly for PTK2, an extension to the project could involve injecting mice with the 
PC-3 cells, harboring the PTK2 amplification, and treating the mice with the TAE226 
inhibitor to notice shrinkage in tumor or a decrease in metastasis.  
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Conclusion 
In conclusion, this study was able to illustrate that FFPE specimen can also be used 
for next generation sequencing protocols. FFPE tissue is a promising alternative to 
fresh frozen material for prostate cancer storage and could be a reliable source of 
material for comprehensive research in routine diagnostics.   
Through the exome sequencing study on CRPC patient samples, two amplified genes, 
YWHAZ and PTK2 both residing on chromosome 8, were identified as potential 
therapeutic targets. Both genes, when inhibited, showed an effect in proliferation and 
invasion in the PC-3 cells. 
Much still remains to be done in the field of CRPC treatment options for patient care, 
but the evolution of next generation sequencing technologies has made it possible to 
study the genetic basis of cancer. In the future, these studies will eventually lead to 
the development of personalized medicine to improve patient care. 
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Appendix I  	  
List of Amplfied Genes 
 
Chromsome 1 	  
 
KIFAP3 GAS5 NCF2 IVNS1ABP  TNNT2 
GORAB ZBTB37 RGL1 RGS1  PHLDA3 
PPPRX1 RC3H1 GLT25D2 TROV2 CSRP1 
FMO3 GPR52 TSEN15 GLRX2 PTPN7 
BAT2D1 CACYBP STX6 KCNT2 PTPN7 
METTL13 MRPS14 MR1 CFH KLHL12 
DNM3 TNN QSOX1 CFHR3 PPF1A4 
PIGC TNR XPR1 (?) ASPM  CHI3L1 
FASLG RFWD2 CACNA1E CRB1 ZC3H11A 
TNFSF4 PAPPA2 DHX9 (?) LHX9 SYT2 
SLC9A11 ASTN1 SMG7 PTPRC KDM5B 
KLHL20 RASAL2 RGS (?) NR5A2 ADORA1 
FMO1 ANGPTL1 NPL KIF14 CHIT1 
XTP2 ABL2 GLUL PKP1  PRELP 
MYOC SOAT1 SMG7 HNTN1 ATP2B4 
VAMP4 nphs2 EDEM3 LAD1 ETNK2 
SNORD79 TDRD5 TRP NAV1 NFASC  
RABGAP1L CEP350 PDC RNPEP RBBP5 
FASLG LAMC1 RFN2 ELF3 DSTYK 
CENPL NMNAT2 PRG4 TMEM9 PVRL4 
TMCC2 CD46 VASH2 CD1E NIT1 
KLHDC8A CD55 PROX1 CD1C DEDD 
PCTK3 DAF PTPN14 PYHIN1 USP21 
LAX1 CR2 KCNK2 IFI16 PPOX 
SOX13 CAMK1G KCTD3 CADM3 SDHC 
MDM4 LAMB3 ESRRG DARC FCRLA 
LRRN2 IRF6 GPATCH2 CRP RGS4 
NFASC SYT14 SPATA17 DUSP23 NUF2 
TMCC2 HHAT MEF2D NESG1 PBX1 
LEMD1 RCOR3 IQGAP3 IGSF8 LMX1A 
ELK4 TRAF5 APOA1BP SLAMF9 TMCO1 
SRGAP2 RD3 AIBP PEX19 MGST3 
RASSF5 NEK2 GPATCH4 NCSTN TADA1 
DYRK3 ANGEL2 HAPLN2 KCNJ9 POU2F1 
IL19 RPS6KC1 BCAN COPA RCSD 
FAIM3 DTL HDGF CD84 DCAFNME7 
PIGR NENF SH2D2A LY9 BLZF1 
FCAMR ATF3 NTRK1 F119 SELP 
PFKFB2 NSL1 FCRL5 TSTD1 SELL 
C4BPB TATDN3 KIRREL F11R TOMM40L 
NR1I3 FCGR3A DUSP12   
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Chromosome 3 
 
IGSF11 MBD4 GYG1 PLXND1 TNIK 
UPK1B TMCC1 HLTF ACRP1 PLD1 
B4GALT4 ATP2C1 HPS3 EIF2A GHSR 
MDSRP NPHP3 CP  CLRN1 NCEH1 
CD80 ASTE1 PFN2 MED12L ECT2 
ADPRH NEK11 RNF13 IGSF10 NLGN1 
PLA1A CPNE4 IFT122 MBNL1 TBL1XR1 
POPDC2 CCRL1 CCDC14 SGEF KCNMB2 
AAT1 UBA5 HIFOO DHX36 ZMAT3 
NR1I2 CDV3 PLXND1 MME MFN1 
GSK3B TF ACRP1 PLCH1 ACTL6A 
FSTL1 RAB6A EIF2A GMPS MRPL47 
HGD AMOTL2 CLRN1 KCNAB1 NDUFB5 
POLQ CEP63 MED12L SSR3 USP13 
HCLS1 KY IGSF10 LEKR1 PEX5L 
GOLB1 EPHB1 MBNL1 CCNL1 FXR1 
IQCB1 PCCB SGEF SHOX2 VWA5B2 
EAF2 MSL2 DHX36 RSRC1 ALG3 
ILDR1 STAG2 MME MFSD1 ECE2 
CD86 TMEN22 PLCH1 SCHIP1 TTC14 
CASR CLDN18 GMPS VEPH1 FXR1 
KPNA1 DZIP1L KCNAB1 MFL1 SOX2 
PARP9 ARMC8 SSR3 IQCJ ATP11B 
SEMA5B MRAS LEKR1 PPM1L MCCC1 
PDIA5 CEP70 CCNL1 SMC4 MCF2L2 
ADCY5 PRR23A SHOX2 NMD3 B3GNT5 
MYLK COPB2 RSRC1 ZBBX KLHL6 
KALRN RBP1 MFSD1 SERPINI2 ABCC5 
UMPS BDR1 SCHIP1 WDR49 HTR3D 
SLC41A3 FAIM VEPH1 GOLIM4 AP2M1 
SNX4 SPSB4 GYG1 MECOM THPO 
ROPN1B ACPL2 HLTF EVI1 TRA2B 
MCM2 ZBTB38 HPS3 MYNN VPS8 
ABTB1 RASA2 CP  SAMD7 PARL 
ACAD9 RNF7 PFN2 CLDN11 LIPH 
TRPA1 ATR RNF13 SLC2A2 ETB5 
ZDXC PLOD2 IFT122 FNDC3B DGKG 
GATA2 PLSCR4 CCDC14 TNFSF10 CRYGS 
RAB7A ZIC4 HIFOO PHC3 AHSG 
ISY1 AGTR1 PLXND1 SKIL FETUB 
RFC4 PIGX RNF13 SLC2A2 ETB5 
MASP1 SENP5 TEMEM44 TNK2 LRCH3 
BCL6 LPP DLG1 NCBP2 EIF4G1 
TP63 IL1RAP IQCG MF12 CLCN2 
OPA1 FGF12 APOD BDH1 CHRD 
MAP3K13 ZDHHC19 RAD54B ST6GAL1 LMLN 
IGF2BP2 PCYT1A UBXN7 TBCCD1  
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Chromosome 8 
 
RLBP1L1 IMPA1 UQCRB EIF3H FAM49B 
ASPH AZFAND1 PTDSS1 MED30 HHLA1 
YTHDF3 SNX16 SDC2 SAMD12 SLA 
MYBL1 REX01L1 MATN2 COL14A1 MYC 
COPS5 ESRP1 POP1 ATAD2 ASAP1 
CSPP1 E2F5 RGS22 WDYHV1 ADCY8 
CPA6 MMP16 OSR2 FBOX32 TG 
SULF1 RIPK2 GRHL2 ANXA13 SLA 
TRAM1 OSGIN2 NCALD TATDN1 ZFAT 
LACTB2 SLC26A7 RRM2B ENPP2 TRAPPC9 
XKR9 PDP1 UBR5 DERL1 EIF2C2 
STAU2 CDH17 BAALC WDR67 PTK2 
UBE2W NBN RIMS2 ZHX1 ESRP1 
TCEB1 DECR1 DPYS MTSS1 PABPC1 
GDAP1 RUNX1T1 ANGPT1 MTBP YWHAZ 
ZFHX4 INTS8 GOLSYN TRPS1 KLF10 
PKIA VPS13B OXR1 MYC AZIN1 
IL7 FBX043 RSPO2 TMEM71 TATDN1 
STMN2 SNX31 NUDCD1 PHF20L1 NDUFB9 
HEY1 PABPC1 ENY2 WISP1 NSMCE2 
MRPS28 YWHAZ KCNV1 NDRG1 KHDRBS3 
JPH1 NCALD TRPS1 ST3GAL1 FAM49B 
PI15 GEM CSMD3 KHDRBS3 HHLA1 
SLA ASAP1 TG ZFAT EIF2C2 
MYC ADCY8 SLA TRAPPC9 PTK2 
ESRP1 KLF10 NDUFB9 KHDRBS3 HHLA1 
PABPC1 AZIN1 NSMCE2 KHDRBS3 TATDN1 
YWHAZ TATDN1    
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Chromosome 11 
 
LPXN  WDR74 CAPN1  MRPL21 CTTN 
ZFP91  SNHG1 MEN1 LRP5  DHCR7 
GLYAT SNORD22 EHD1 TPCN2 IL18BP 
GATFC SLC3A2 TM7SF2 PFFIA1 NUMA1 
FAM111A NXF1 SYVN1 SHANK2 LRTOMT 
DTX4  UST6 POLA2 ORAOV1 FOLR1 
PATL1 HRASLS5 DPF2 MYEOV  PDE2A 
STX3 LGALS12 FRMD8 ANO1 CLPB 
GIF RTN3 LTBP3 CTTN ARAP1 
MS4A3 NUDT22 RELA DHCR7 P2RY6  
CD6 DNAJC4 CFL1 IL18BP PLEKHB1 
CYBASC3 GPR137 FIBP NUMA1 PAAF1 
DDB1  KCNK4 CTSW LRTOMT CHRDL2 
ZP1 ESRRA KLC2 FOLR1 GDPD5 
VWCE PRDX5 RIN1 PDE2A NEU3 
DAK MARK2 PELI3 CLPB PPME1 
SYT7 O2UB1 DPP3 ARAP1 UVRAG 
FADS1 TRPT1 BBS1 P2RY6  APHC 
VMD2 VEGFB PC PLEKHB1 INTS4 
BEST1 FKBP2 POLD4  PAAF1 MOGAT2 
ASRGL1 PLCB3 PPP1CA CHRDL2 CAPN5  
EEF1G BAD CORO1B MRPL21 MYO7A 
MTA2 PYGM DOC1R LRP5 (?) APHC 
EML3 FAU CABP2 TPCN2 LRRC32 
GANAB SF1 GSTP1 PFFIA1 WNT1  
UBXN1 STIP1 NDUFV1 SHANK2 CAPN5  
BSCL2 ATL3 TCIRG1 ORAOV1  POLD3 
TAF6L NRXN2 CHKA MYEOV  OVOL1 
STX5 ZFPL1 SAPAS3 ANO1 SNX32 
EFEMP2 SART1 MRPL11 ATG18L2 RPS6KA4  
CFL1 EIF1AD  TMEM134 FCHSD2 RASGRP2  
FIBP BANF1 SUV420H1 SNHG1 SLC3A2 
FOSL1 SF3B2 STARD10   
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Chromosome 16 
 
HN1L IL32 PARN M6PR TNRC6A 
NME3 NAT15 BFAR NOMO2 SLC5A11 
EME2 TRAP1 DNASE1L2 RPS15A JMJD5 
SPSB3 CREBBP RNPS1 SMG1 IL4R 
NUBP2 ADCY9 ABCA3 TMC7 IL21R 
IGFALS NMRAL1 TBC1D24 SYT17 GSG1L 
HAGH HMOX2 PGP TMC5 XPO6 
FAHD1 MGRN1 E4F1 IQCK EIF3CL 
RPS2 ANKS3 DCI GPRC5B CLN3 
TBL3 GLYR1 AMDHD2 ACSM2A SULT1A1 
NOXO1 UBN1 PDPK1 THUMPD1 ATXN2L 
GFER NAGPA PRSS27 ERI2 SH2B1 
PKD1 A2BP1 HCFC1R1 LYRM1 ATP2AI 
MLST8 ABAT CCDC64B TMEM159 RABEP2 
CCNF PMM2 ZSCAN10 ZP2 CD19 
PDPK1 USP7 ZNF434 CRYM CLDN9 
SRRM2 GRIN2A UNQ2771 IMAA THOC6 
PRSS33 NUBP1 CLUAP1 IGSF6 SNX29 
FLYCH2 CIITA PDXDC1 OTOA MKL2 
KREMEN2 LITAF NTAN1 NPIPL3 NDE1 
PAQR4 RSL1D1 RRN3 VWA3A ABCC1 
PKMYT1 GSPT1 NPIP EEF2K PRKCB 
RBBP6     
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Chromosome 17 
 
MRPL27 VEZF1 CSH2 ACOX1 PCYT2 
EME1 MKS1 CYB561 SRP68 SIRT7 
ACSF2 LPO KCNH6 LGICZ MAFG 
CHAD BZRAP1 MAP3K3 EXOC7 HEXDC 
RSAD1 RNF43 LIMD2 SPHK1 NARF 
EPN3 Sep-04 STRADA PHBDF2 ICAM2 
SPATA20 TEX14 DDX42 CYGC DDX5 
CACNA1G RAD51C PSMC5 PRCD TEX2 
ABCC3 TRIM37 CSHL1 JMJD6 SMURF2 
TOB1 PRR11 GNA13 MFSD11 ARMC7 
SPAG9 DHX40 RGS9 TMC6 HN1 
MBTD1 TMEM49 AXIN2 AFMID SUMO2 
CA10 HEATR6 HELZ BIRC5 GGA3 
KIF2B CLTC BPTF PGS1 MIF4GD 
TOM1L1 TUBD1 WIPI1 DNEL2 TSEN54 
COX11 RNFT1 AMZ2 USP36 SEC14L1 
STXBP4 PPM1D KCNJ16 CANT1 ARHGDIA 
HLF BCAS3 KIF19 CARD14 ANAPC11 
PCTP TBX4 CD300A GAA PYCR1 
NOG BRIP1 FDXR SGSH STRA13 
DGKE INTS2 SLC16A5 ACTG1 GPS1 
TRIM25 TLK2 RAB37 AZI1 DUS1L 
AKAP1 ACE LLGL2 GCGR CSNK1D 
CUEDC1 DCP1 ITGB4 P4HB  
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Chromosome X 
 
NLGN4X PIR ZFX PCTK1 CCNB3 
HDHD1A BMX PDK3 ZNF41 FAM156A 
STS ASB11 PCYT1B ARAF RIBC1 
PINPL4 ACE2 POLA1 TIMP1 PHF8 
FAM9B CTPS2 MAGEB6 ELK1 TRO 
SHROOM2 RBBP7 GK UXT KLF8	  (?) 
MID1 REPS2	   DMD ZNF182 USP51 
ARHGAP6 NHS BCOR SSX4B SPIN3 
AMELX SCML1 CYBB FTSJ1 ASB12 
WWC3 RAI2 SYTL5 PORCN LAS1L 
TBL1X BEND2 SRPX DATL1 VSIG4 
HCCS SCML2 RPGR OATL1 AR 
PRPS2 CDKL5 MID1IP1 WDR13 OPHN1 
MSL3 PPEF1 DDX3X SUV39H1	  (?) STARD8 
EGFL6 PHKA2 CASK PQBP1 EDA2R 
TCEANC GPR64 NYX OTUD5 VSIG4 
TRAPPC2	   PDHA1 MAOB EBP WDR13 
GMP6B YY2 KDM6A HDAC6	  (?) TIMM17B 
GLRA2 CNKSR2	   ZFN673 MAGIX PQBP1 
FANCB MBTPS2 SLC9A7 CCDC22 WDR45 
MOSPD2 SMS RGN FOXP3 RBM10 
PIGA PHEX UBA1 JM4 SAT1 
OFD1 ACOT9 PHF16 AKAP4 ASB9 
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Appendix II 
 
List of Deleted Genes 
 
Chromosome 8 
 
LONRF1 MTMR7 NPM2 NKX3-­‐1 ESCO2 
DLC1 MTUS1 FGF17 ADAM28 PBK 
SGCZ FGF20 EPB49 GNRH1 ELP3 
DM004805 ZDHHC2 FAM160B2 KCTD9 RC74 
MSR1 VPS37A NUDT18 CDCA2 INTS9 
MTUS1 MTMR7 REEP4 NEFM DUSP4 
SH2D4A SLC7A2 LG13 DOCK5 RBPMS 
HT-­‐15 PDGFRL SFTPC GNRH1 GSR 
NEFM FGL1 BMP1 BNIP3L UBXN8 
EBF2 PCM1 PHYHIP DPYSL2 PURG 
RB3 ASAH1 POLR3D PTK2B WRN 
FZD3 CSGALNACT1 PIWIL2 ADRA1A NRG1 
THEM66 PSD3 SLC39A14 EPHX2 FUT10 
WRN SH2D4A PPP3CC SCARA2 BIN3 
NAT1 INTS10 SORBS3 CCDC25 EGR3 
STMN4 SLC18A1 PDLIM2 FBXO16 RHOBTB2 
TUSC3 GFRA2 CHMP7 PNMA2 CLU 
HRF2 DOK2 LOXL2 STMN4 ENTPD4 
CNOT7	   XPO7    
 
Chromosome 11 
 
ME3 MRE11A CASP4 DDX10 DRD2 
PRSS23 SESN3 PDGFD ZC3H12C ZBTB16 
FZD4	  (?) CEP57 CASP5 RDX ZW10 
CTSC MTMR2 CASP1 BTG4	   USP28 
GRM5 CNTN5 GRIA4 LAZN HTR3B 
TYR PGR CWF19L2	   PPP2R1B RBM7 
NOX4 PR ABH8	   ALG9 CADM1 
NAALAD2 YAP1 ELMOD1 DIXDC1 BCO2 
CHORDC1 DYNC2H1 GUCY1A2 PIH1D2 NCAM1 
FAT3 DD1 RAB39	   ALG9 TMPRSS5 
CCDC67 CASP12 CUL5 DLAT TTC12 
TAFD1 CASP4 ACAT1 IL18 EXPH5 
MED17 PDGFD	   NPAT PTS CASP1 
HEPHLI CASP5 ATM NCAM1 PANX1 
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Chromosome 16 
 
CDH11 SLC12A4 HYDIN NUDT7 SCL9A5 
CDH5 DUS2L AP1G1 MAF PLEKHG4 
TK2 ACD CALB2 CENPN RORBP70 
CKLF CENPT DODH ATMIN NFATC3 
CMTM1 EDC4 HP PKD1L2 PMFBP1 
CDH16 KCC1 RFWD3 BCDO MMP2 
CES2 CDH1 MLKL CDH13 AMFR 
TRADD HAS3 WDR59 TAF1C MT2A 
HSF4 NFAT5 ZNRF1 ATP2C2 NLRC5 
NOL3 DOX19B BCAR1 COTL1 RSPRY1 
ELMOS3 NQ01 CFDP1 USP10 CETP 
FHHOD1 WWP2 KARS IRF8 CPBE2 
TPPP3 PDPR CNTNAP4 TRADD COQ9 
RLTPR FUK MON1B EXOCL3 DOK4 
RANBP10 COG4 WWOX LRRC29 GPR56 
KIFC3 KLKBL4 NDRG4 CDH8 CDH1 
 
 
Chromosome 17 
 
XAF1 MPDU1 CHD3 PMP22 TOP3A 
FBXO39 FXR2 RANGRF CDRT1 SHMT1 
TEKT1 TP53 NDEL1 ZSWIM7 SHBG 
ALOX12E CHD3 MYH10 NCOR1 WRAP53 
BCL6B RANGRF WDR16 TTC19 DNAH2 
ASGR2 NDEL1 USP43 MPRIP CNTROB 
DLG4 MYH10 GAS7 PEMT DLG4 
ACADVL WDR16 MYH13 SREBF1 ACADVL 
PHF23 USP43 MAP2K4 ATPAF2 PHF23 
DULLARD GAS7 SHISA6 DRG2 CLDN7 
CLDN7 MYH13 MYOCD FLII EIF5A 
EIF5A MPDU1 RICH2 SMCR7 PLSCR3 
NEURL4 FXR2 ELAC2 TOM1L2 DVL2 
SENP3 TP53 COX10 LRRC48 GPS2 
TNK1 FGF11 CHRNB1 POLR2A TNFSF13 
EIF4A1 ALOXE3    
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Chromosome 18 
 
NOL4 ZBTB7C NEDD4L 
DTNA DYM CCBE1 
MAPRE2 RPL17 GRP 
ZNF24 MYO5B VPS4B 
GALNT1 MBD1 PIGN 
ELP2 CXXC1 CDH7 
PIK3C3 MAPK4 TMX3 
SETBP1 MRO SOCS6 
SLC14A1 DCC CBLN2 
RNF165 MBD2 NET01 
LOXHD1 POLI CTDP1 
PIAS2 TCF4 NFATC1 
HDHD2 NEDD4L BRUNOL4 
HDHD2 TXNL1 FHOD3 
SMAD2 FECH  
 
 
Chromosome 19 
 
GP1 SHKBP1 POU2F2 DMWD HNRNPUL1 
GRAMD1A LTBP4 CEACAM1 KLC3 (E)GNL2 
HPN ATP5SL FBL ERCC2 CLPTM1 
LSR POU2F2 AKT2 HIF3A SNRPD2 
USF2 CEACAM1 PLD3 DAT3 SYMPK 
DMKN FBL DEDD2 PRKD2 PSG11 
ETV2 AKT2 ADCK4 STRN4 CLPTM1 
SNX26 PLD3 TMEM91 DHX34 QPCTL 
APLP1 DEDD2 ARGHEF1 MEIS3 RSHL1 
ALKBH6 ADCK4 ERF SAE1 FOSB 
CAPNS1 TMEM91 PSG11 NAPA RTN2 
HCST ARGHEF1 ETHE1 ALKBH6 EML2 
RASGRP4 ERF PLAUR CAPNS1 RBM42 
SIRT2 PSG11 GEMIN7 RASGRP4 KIRREL2 
KFKBIB ETHE1 FOSB SARS2 DMPK 
HKR1 PLAUR RTN2 MRPS12 ATP5SL 
SPRED3 SHKBP1 VASP LTBP4 PAK4 
HNRNPL LTBP4 EML2 NUMBL  
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Chromosome 22 
 
TUBA8 AIFM3 CRKL MAPK1 XBP1 
USP18 LZTR1 BCR TOP3B EMID1 
GGTP3 SEC14L2 GGT2 ZNF280B EWSR1 
PRODH HP2XM PI4KA PRAME GAS2L1 
SLC25A1 SLC7A4 HIC2 MTMR3 AP1B1 
CLTCL1 THAP7 UBE2L3 GATSL3 THOC5 
GSC2 CRKL PPIL2 PIK31P1 NF2 
HIRA BCR YPEL1 CARD10 SMTN 
UFD1 GGT2 PPM1F SH3BP1 SF11 
CLDN5 PI4KA MAPK1 TRIPBP YWHAH 
TBX1 HIC2 TOP3B PLA2G6 RFPL2 
5SELPT UBE2L3 ZNF280B WBP2NL BPIL2 
GNB1L PPIL2 PRAME 2D7P1 FBXO7 
TRXR2A YPEL1 MTMR3 POLDIP3 TOM1 
COMT PPM1F GATSL3 A4GALT MMC5 
ARVCF MAPK1 PIK31P1 ARFGAP3 RASD2 
RANBP1 TOP3B CARD10 PACSIN2 MB 
ZDHHC8 ZNF280B SH3BP1 MIOX RBM9 
DGCR8 PRAME TRIPBP LMF2 MYH9 
TRMT2A MTMR3 PLA2G6 NCAPH2 RABL2B 
RTN4R GATSL3 CRKL SCO2 CHEK2 
DGCR6L PIK31P1 BCR TYMP YPEL1 
RIMBP3 CARD10 GGT2 ODF3B PPM1F 
USP41 AIFM3 PI4KA CPT1B SLC7A4 
ZHF74 LZTR1 HIC2 CHKB THAP7 
SCARF2 SEC14L2 UBE2L3 ARSA MED15 
KLHL22 HP2XM PPIL2 SHANK3 PI4KA 
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